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INTRODUCTION       
According to World Health Organization (WHO) (1) there are 39 million people blind in 2010 in the 
whole world. 20.5% of these patients are in India which is the second highest, next to China. 
Glaucoma accounts for second most common cause of blindness, second only to cataract
1
.  
 
The only modifiable risk factor in preventing the progression of glaucoma is Intra Ocular Pressure 
(IOP). IOP can be reduced by different modalities of treatment which includes medications, laser 
treatment and surgery. Surgery is indicated if IOP is not controlled on maximal medical therapy with 
antiglaucoma medications and when compliance and affordability are issues. Co-existing cataract 
offers an opportunity for glaucoma surgery at the same sitting.  
 
Trabeculectomy is the most common type of surgery done for glaucoma
 
(2). The main cause of 
failure of trabeculectomy is postoperative subconjunctival scarring in the filtering bleb, which is 
mainly mediated by fibroblast proliferation, migration and contraction. Conjunctival scarring can 
cause blockage of aqueous outflow by creating adhesions between conjunctiva and episclera and 
between scleral flap and underlying tissues. 
 
Most of the currently used adjunctive agents that modulate wound healing are 5 Fluorouracil (5-FU) 
and Mitomycin C (MMC) are effective in limiting the scarring process. However they are associated 
with adverse effects such as hypotony, cystic thin avascular bleb, bleb leakage, bleb infection and 
endophthalmitis (3-5).To overcome these complications other agents to modulate wound healing 
have been introduced. 
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The Ologen collagen matrix implant is a disc-shaped porcine derived biodegradable collagen matrix 
that has been developed to prevent excessive scarring after trabeculectomy. It is composed of a three-
dimensional porous structure of collagen & glycosaminoglycan copolymers. During trabeculectomy, 
the implant is placed on top of the sclera flap before the conjunctiva is closed over it. The implant 
regulates aqueous flow by keeping pressure on top of the sclera flap and by acting as a reservoir as 
aqueous humour gets absorbed into its porous structure. The collagen matrix provides a scaffold for 
growth of fibroblasts and guides the fibroblasts to grow through the matrix pores in a random and 
diffuse fashion rather than in an organised way, thus altering tissue remodelling in the trabeculectomy 
wound and reducing scar formation. The eventual result after resorption of the matrix would result in 
a loosely structured filtering bleb. Ologen has been used in trabeculectomy alone as well as in   
trabeculectomy combined with cataract extraction by phacoemulsification.  
 
There are three Randomized controlled trials (RCT) comparing MMC & Ologen in trabeculectomy 
surgery. Two of these studies (6, 7) have shown that both MMC and Ologen are equally efficacious 
in controlling IOP. However the RCT by Rosentreter et al., (8) and a case control study by Boey et 
al., (9) showed MMC to be superior to Ologen. These studies have not addressed the use of post-
operative use of 5 FU. All the RCTs have compared MMC and Ologen in trabeculectomy alone. 
There are no RCTs comparing the two agents in phacotrabeculectomy. There is only one 
interventional case control study comparing the two agents which has shown MMC to be superior to 
Ologen.  
 
Different races show different response to wound healing. There is no Indian clinical trial comparing 
the two agents in trabeculectomy or phacotrabeculectomy. Only one published study by Tanuj dada et 
al., (10) was a retrospective analysis of patients undergoing trabeculectomy with Ologen and MMC. 
At the end of 1 year follow up IOP was lower in the combined group than controls.  
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Therefore more Indian studies especially Randomized controlled trials are needed to compare the 
efficacy of the two agents. So we conducted this RCT to compare phacotrbeculectomy with MMC 
versus Ologen in Indian eyes. We also looked into the requirement of additional interventions like 
post-operative antifibrotic agents (5 FU) and needling.  
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AIMS AND OBJECTIVES 
 
AIM:  
To compare the safety & efficacy of MMC versus Ologen in patients undergoing 
phacotrabeculectomy surgery. 
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OBJECTIVES:  
1. To compare the efficacy of MMC versus Ologen in phacotrabeculectomy. 
2. To look at the bleb morphology in phacotrabulectomy with MMC versus Ologen. 
3. To derermine the complications in phacotrabulectomy with MMC versus Ologen. 
4. To look for differences in the requirement of additional interventions like injection 5-
FU, needling and secondary surgical interventions in the two groups.  
5. To compare the need for additional antiglaucoma medications required post 
operatively in the two groups.  
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LITERATURE REVIEW 
 
Glaucoma is a chronic optic neuropathy characterized by specific and progressive 
injury to the retinal ganglion cells resulting in damage to the optic nerve head and 
retinal nerve fiber layer
 
(11)resulting in characteristic disc and field changes. 
 
TERMINOLOGIES 
 
Chronic open-angle glaucoma (COAG): Sheild’s textbook of glaucoma (12) doesn’t define 
POAG as a separate entity. But describes it as a COAG and defines it as a multifactorial optic 
neuropathy in which there is characteristic atrophy of the optic nerve. It is typically 
characterized by the following three criteria: (a) an intraocular pressure (IOP) consistently 
above 21 mm Hg in at least one eye; (b) an open, normal-appearing anterior chamber angle 
with no apparent ocular or systemic abnormality that might account for the elevated IOP; and 
(c) typical optic nerve head damage and/or glaucomatous visual field damage
 
(12). 
 
Primary open-angle glaucoma (POAG): A chronic, progressive optic neuropathy that is 
accompanied by a characteristic cupping and atrophy of the optic disc, visual field loss, open 
angles, and no obvious causative ocular or systemic conditions
 (13). IOP is above the ‘normal 
range’ which is defined as IOP above 2 Standard deviations from mean i.e.21 mm Hg. It is 
generally a bilateral disease but commonly asymmetric at presentation. 
 
Ocular Hypertension (OHT): Patients who have the first two criteria for COAG (i.e., an 
IOP above 21 mm Hg for which there is no apparent cause), but whose optic nerve heads and 
visual fields are normal are said to have ocular hypertension
 
(12). 
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Individuals with IOPs of 21 mmHg (the statistical upper end of the ‘normal’ range) or 
greater, normal visual fields, normal optic discs, open angles, and absence of any ocular or 
systemic disorders contributing to the elevated IOPs are referred to as having ocular 
hypertension
 
(13). 
 
Normal Tension Glaucoma (NTG): Open, normal-appearing anterior chamber angles with 
glaucomatous optic nerve head and visual field damage despite pressures that have never 
been documented above 21 mm Hg
 
(12). 
 
Primary angle closure suspect (PAC suspect): Greater than 270° of irido-trabecular contact 
plus absence of peripheral anterior synechiae (PAS) plus normal IOP, disc, and visual field
 
(13). 
 
Primary angle closure (PAC): Greater than 270° of irido-trabecular contact with either 
elevated IOP and/or PAS plus normal disc and visual field examinations
 
(13). 
 
Primary angle-closure glaucoma (PACG): Greater than 270° of irido-trabecular contact 
plus elevated IOP plus optic nerve and visual field damage
 
(13). 
 
EPIDEMIOLOGY 
 
 
According to the study done by WHO in 2010, there are about 39 million people blind in the 
whole world. India accounts for 20.5 % of all blind people in the world, second only to China 
which accounts for 20.9% cases.  Of all the causes of blindness, glaucoma is the second most 
common cause after cataract. It accounts for 8% of all global causes of blindness
 
(1). 
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Asians account for 47% of all cases of glaucoma and 87% of those with Angle closure 
glaucoma. Number of people worldwide with Open angle glaucoma and Angle closure 
glaucoma has been estimated to increase to 79.6 million by 2020. Out of these, 5.9 million 
people with Open angle glaucoma and 5.3 million people with Angle closure glaucoma will 
be bilaterally blind by 2020 (14). 
 
Prevalence studies of glaucoma have been done in different parts of India which includes 
Vellore (15), Andhra Pradesh (16, 17), Chennai (18, 19), Madurai (20), West Bengal (21)and 
Chhattisgarh (22). It has been estimated that about 11.2 million in the age group of 40 years 
and above have glaucoma in India. Out of this 6.48 million people have POAG and 2.4 
million people have PACG (23). Table 1 describes the prevalence of different types of 
glaucoma in these studies. 
Table 1: Glaucoma prevalence in India 
 POAG PACG OHT 
Vellore Eye 
study(15) 
0.41% 4.32% 3.08% 
Andhra Pradesh 
Eye Disease 
Study(16, 17) 
2.56% 1.08% 0.42% 
Chennai 
Glaucoma 
study(18, 19) 
3.51% 0.88%  
Aravind 
Collaborative 
Eye study(20) 
1.7% 0.5%  
 
In the West Bengal Study (21) prevalence of glaucoma was found to be 3.4% with POAG 10 
times more common than PACG. In another study done in Chattisgarh (22) prevalence of 
glaucoma was found to be 3.68%. Out of these POAG, PACG, Secondary glaucomas and 
OHT accounted for 13.1%, 21.2%, 21.2% and 14.5% of cases respectively. 
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MANAGEMENT OF GLAUCOMA 
 
The main aim of treatment is to prevent progression of functional impairment of vision within 
the patient’s lifetime by slowing the rate of ganglion cell loss closer to that of normal 
population (about 5000/year). The only known modifiable risk factor for glaucoma is intra 
ocular pressure (IOP). It has been established by landmark Randomized Controlled Trials that 
reduction in IOP reduces progression in glaucoma. Early Manifest Glaucoma Trial (24) 
showed that by lowering the IOP by 25% the chance of progression of the disease reduced 
from 62% in untreated patients to 45% in the treated patients. The current mainstay of 
treatment of POAG and NTG is reduction of IOP.  
 
The IOP reduction required to halt progression needs to be individualized.   Generally in most 
patients 25- 30% reduction of IOP from the baseline is desirable. However other factors like 
degree of glaucomatous disc damage, visual field defects, age of the patient, and the central 
corneal thickness and are important parameters to be considered when determining target 
IOP.  
 
Target IOP 
 
The American Academy of Ophthalmology Preferred Practice Pattern Panel has defined 
target IOP as the upper limit of the range of measured intraocular pressures adequate to stop 
progressive pressure-induced injury of the optic nerve head (25). The European Glaucoma 
Society Panel (26) has defined target IOP as the estimate of the mean IOP obtained with 
treatment that is expected to prevent further glaucomatous damage. Another definition 
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provided by Henry Jampel (27) is that the target IOP is the highest IOP in a given eye which 
does not contribute to the development of clinically apparent glaucomatous optic nerve 
damage. This definition takes into account the fact that glaucomatous damage of the optic 
nerve head is not important as long as it is not apparent in visual function tests and to the 
patient.  
 
Determinants of Target IOP are: 
 IOP level at which optic nerve damage occurred 
 Present IOP 
 Extent and rate of progression of glaucomatous damage, if known 
 Presence of other risk factors 
 Age of the patient 
 Expected life span 
 Medical history 
The patient with glaucoma needs lifelong follow up. On follow up optic disc and field 
changes are monitored. In the event of further progression, the target IOP has to be reset at a 
lower level. In case of stable parameters, target IOP has to be reset at a lower level and 
antiglaucoma medications decreased to improve the quality of life of the patient. Different 
formulae have been put forward to define target IOP. 
Emperical formula for target IOP by Jampel et al., (27):  
        Target IOP = [Initial IOP-(1-Initial IOP/100) - Z + Y±1] 
Here ‘Z’ denotes the severity of optic nerve damage and ‘Y’ denotes the effect on the quality 
of life. The grading of these factors has been shown in table 2. 
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Table 2: Jampel’s formula for target IOP 
Value Z= Optic Nerve Damage Severity Factor Y= Burden Of Therapy Factor 
0 Normal disc and Normal visual field No effect on QOL 
1 Abnormal Disc and Normal visual field Minimal effect on QOL 
2 Visual field loss not threatening fixation Moderate effect on QOL 
3 Visual field loss threatening or involving fixation Significant effect on QOL 
 
 
Modified from Jampel’s formula (28): 
Target IOP = Maximum IOP – Maximum IOP% - Z  
 
Advanced Glaucoma Intervention Study Formula (29): 
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American Academy of Ophthalmology Guidelines describes target IOP as shown in table 3 
(25): 
Table 3: AAO Guidelines 
Grade  Description  Target IOP* 
Mild Characteristic optic nerve abnormalities are 
consistent with glaucoma, but the visual field is 
normal  
20% 
Moderate Visual field abnormalities exist in one hemifield and 
are not within 5° of fixation and Normal Tension 
Glaucoma 
30% 
Severe Visual field abnormalities exist in both hemifields, or 
visual field loss is within 5° of fixation 
40% 
*(% Reduction from Baseline) 
 
The various approaches to achieve this goal include medical therapy, laser trabeculoplasty, 
filtering surgery, and cyclodestructive procedures, each of which has its own risks and 
benefits.  
 
Medical therapy 
 
Medical therapy involves administration of antiglaucoma medications to the patient to 
achieve the target IOP. Topical medications (eye drops) include: 
1. β adrenergic antagonists 
2. Prostaglandin analogues 
3. Carbonic anhydrase inhibitors 
4. Adrenergic agonists 
5. Parasympathomimetic agents 
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The role of systemic carbonic anhydrase inhibitors and osmotic agents like glycerol and 
mannitol is limited and temporary in open angle glaucoma. It is used in patients with high 
uncontrolled IOP despite topical medications, awaiting surgery to stabilize the IOP prior to 
surgery. However these agents are very essential in the intial management of acute angle 
closure glaucoma. The role of neuroprotective agents is not yet established. 
 
Antiglaucoma medications are ideally started in one eye and one agent at a time - uniocular 
therapeutic trial- in order to establish the efficacy of the drug. Depending on the severity of 
glaucoma and the socioeconomic status of the patient, β blockers or Prostaglandin analogues 
form the first line drugs of choice. Further additional medications and combination therapies 
with two or usually not more than three classes of drugs may be added as per the individual 
patient’s target IOP.  
 
Compliance, affordability, side effects and effect on the quality of life of the patient are to be 
kept in mind before selecting the drug for the individual.   
 
Laser therapy 
 
The second modality of treatment is laser therapy. Different types of laser surgery are as 
follows: 
1. Laser peripheral iridotomy: It is done to prevent or treat pupillary block in angle 
closure. The role of laser PI in open angle glaucoma is limited to pigmentary 
glaucoma in its active phase. 
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2. Laser iridoplasty or gonioplasty: It is indicated in patients with plateau iris syndrome 
to contract the peripheral iris and hence pull it away from the angle. 
 
 
3. Laser trabeculoplasty: ALT is the most commonly performed procedure. It can be of 
different types like argon laser or selective laser or diode laser trabeculoplasty. It is a 
treatment option in a patient with open angle glaucoma when maximum tolerated 
medical therapy is not able to achieve the target IOP. Advanced Glaucoma 
Intervention study was a RCT comparing two treatment sequence: Argon laser 
trabeculoplasty- trabeculectomy- trabeculectomy (ATT) and Trabeculectomy- Argon 
laser trabeculoplasty- trabeculectomy (TAT). They concluded that ATT sequence was 
beneficial for black race and the TAT sequence for the white race (30). However a 
later report didn’t support this view (31). It may also be used as a primary treatment 
for glaucoma and in patients who are non compliant and systemically unfit to undergo 
surgeries. It is especially effective in POAG, pigmentary glaucoma and PEX 
glaucoma. However the IOP reduction achieved by laser is not long lasting as shown 
by various studies.155-162(32-39). 19% - 23% cases fail in the first year followed by 
a failure rate of 5% - 9% per year.160-162 (37-39). At the end of 5 and 10 years, half 
and two third of the patients fail (39). 
  
4. Excimer laser trabeculostomy: It involves making a communication between the 
juxtacanalicular trabecular meshwork and the Schlemm’s canal which are the major 
site of obstruction in open angle glaucoma. Study by Neuhann et al., (40) 
demonstrated a 40% decrease in IOP at 6 months follow up in 14 eyes. 
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5. Cyclophotocoagulation: It involves destruction of the epithelium, stroma and 
vasculature of the ciliary body and hence decreasing the aqueous humour production. 
It is generally used in symptomatic (pain) patients with advanced glaucoma with very 
poor visual prognosis. It is rarely tried as the last resort when all other modalities of 
treatment fail or patients are systemically unfit to undergo glaucoma surgical 
procedures. 
 
Surgical treatment 
 
The third and one of the most important modality of treatment is surgical treatment. 
Indications of surgery: 
1. Patients noncompliant with medical management. 
2. Patient not affording antiglaucoma medications. 
3. Patients non tolerant to the side effects of the antiglaucoma medications. 
4.  Uncontrolled IOP and progression of optic disc and field changes despite maximum 
tolerated medical therapy and laser therapy. 
5. Advanced glaucomatous field defect threatening central vision. 
6. Combined with cataract surgery if IOP is borderline high or there is advanced 
glaucomatous field and disc changes. 
 
Collaborative Initial Glaucoma Treatment Study showed that surgical therapy achieves better 
IOP control than medical therapy but visual field progression was similar in the two groups
 
(41). 
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Surgical therapy is more likely to keep IOP at a lower level for longer period of time
 
(42-46). 
In comparison to medications, surgery is likely to ensure stable low IOP throughout the day 
thus reducing the diurnal variation of IOP and hence progression of glaucoma despite 
treatment. Hence surgery may be indicated in those patients with progression of glaucoma 
despite documentation of adequate reduction in IOP on medications. Quality of life may be 
better in the surgical group on the long run. While quality of life may be affected adversely 
due to side effects of the antiglaucoma medications. Surgery is less dependent on the 
compliance of the patient. Cost of the surgery, if not associated with complications may be 
less than the life time need for multiple antiglaucoma medications. 
The flowchart below explains the different types of glaucoma surgery. 
 
 
 
 
 
 
 
 
 
In penetrating glaucoma surgeries a fistula is created into the anterior chamber so that 
aqueous flows out to the subconjuctival space forming a bleb. Full thickness filtering 
surgeries were the first type of glaucoma surgery introduced. They are obsolete now. In these 
surgeries the fistula connecting the sub conjunctival space to the anterior chamber is covered 
only by the conjunctiva and tenon’s capsule. They are therefore associated with more chances 
GLAUCOMA SUGERY 
FULL THICKNESS 
FILTERING SURGERY 
NON PENETRATING 
SURGERY 
PARTIAL THICKNESS OR 
GUARDED FILTERING SURGERY 
PENETRATING 
SURGERY 
GLAUCOMA DRAINAGE 
DEVICES 
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of hypotony, shallow anterior chamber, premature cataract and bleb failure. They include 
following types of surgery: 
1. Sclerectomy 
2. Thermal sclerostomy 
3. Trephination 
4. Iridencleisis 
 
Sclerectomy involves creating a limbal fistula with different techniques. Anterior lip 
sclerectomy was first introduced by LaGrange in 1906 (47). In this surgery a full thickness 
limbal fistula was made and then a piece of tissue was excised from the anterior aspect of the 
wound. 3 years later it was modified by Holth (48) when he used a punch to create the 
sclerectomy. Iliff and Hass (49) further introduced the technique of posterior sclerectomy 
which became popular in mid 20
th
 century. 
 
Thermal sclerostomy was first described by Preziosi in 1924 (50). In this surgery an 
electrocautery was used to make the limbal fistula. It was later modified by Scheie (51) in 
which limbal incision was first marked with a scratch and then the cautery was applied. 
 
In 1909 Elliot (52) and Fergus (53) introduced the technique of trephination at the 
corneolimbal junction. Elliot (54) further modified it by doing trepination more anteriorly at 
the sclerocorneal junction. However it was associated with the formation of thin blebs with 
increased chances of infection. Therefore Sugar (55) modified it to limboscleral trephination 
in which the trephination was done more posteriorly.   
 
- 26 - 
 
In iridencleisis, iris tissue was incarcerated in the limbal incision and it was supposed to act 
as a wick and facilitate aqueous outflow. However it is now an obsolete surgery because of 
the increased chances of sympathetic ophthalmitis.    
 
In non penetrating surgeries anterior chamber is not entered and the trabecular meshwork is 
left intact. This reduces the chances of hypotony, overfilteration and the consequent sequale. 
Two lamellar sclera flaps are made and the deeper flap is excised.  
 
The first non penetrating surgery known as sinusotomy was first introduced by Krasnov (56). 
In this surgery Schlemm’s canal is exposed after excision of a small strip of sclera. In another 
type of non penetrating surgery known as nonpenetrating trabeculectomy deep dissection is 
done to the level of Schlemm’s canal to expose the trabecular meshwork but leaving it intact 
(57). 
 
At present there are mainly two types of non penetrating surgery performed: 
1. Deep sclerectomy 
2. Viscocanalostomy  
 
In the former a Descemet’s window is created through which aqueous humour flows into the 
subconjunctival space forming a bleb. A modification is placement of a collagen implant in 
the scleral bed which increases the success rate of the surgery (58-60). In the latter surgery a 
filtering window is created and then a viscoelastic agent is used to dilate the Schlemm’s canal 
which is supposed to create microruptures in the trabecular meshwork. However these 
surgeries are technically more demanding and require meticulous dissection without entering 
the trabecular meshwork.  
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Trabeculectomy is the prototype of the guarded filtering surgery performed routinely by most 
glaucoma surgeons worldwide (2). The concept of trabeculectomy was first put forward by 
Sugar in 1961 (61)and popularised by Cairns in 1968 (62).The basic mechanism of surgery is 
to create a fistula at the limbus which allows the aqueous humour to flow out, past the angle 
of anterior chamber, where the basic pathology lies. This fistula is covered with a partial 
thickness sclera flap to control the aqueous outflow and consequent hypotony. The 
outflowing aqueous accumulates under the conjunctiva forming a filtering bleb. Amount of 
flow depends on the tightness and thickness of the sclera flap as well as the overlap between 
the trabeculectomy site and the sclera flap. Most/Some studies have shown penetrating 
glaucoma surgeries to be superior to nonpenetrating surgeries in lowering IOP
 
(63-65). 
 
Glaucoma drainage devices are the surgery of choice after failed filtering surgery with 
antifibrotic agents in adults as well as in congenital glaucoma. They are the primary surgical 
choice in conditions where primary trabeculectomy is likely to fail like neovascular glaucoma 
(NVG), uveitic glaucoma and angle recession glaucoma. They can be either valved or non 
valved implants. Baerveldt implant and Molteno implant are the examples of the former 
while Ahmed glaucoma valve and Krupin implant are examples of the latter. 
 
COMBINED CATARACT AND GLAUCOMA SURGERY 
 
In a patient with both cataract and glaucoma, the type of surgery has been a matter of 
controversy. Sequential cataract and glaucoma surgery and combined surgery are the two 
options. Two important developments have contributed to the increased rate of combined 
surgery as compared to sequential cataract and glaucoma surgery. The first of these is the 
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evolution of phacoemulsification surgery with foldable intra-ocular lenses. Decreased wound 
size, decreased postoperative inflammation and different choices for surgical entry sites have 
led to early post-operative rehabilitation and good visual outcome. The second is the 
introduction of antifibrotic agents in glaucoma surgeries which enhance the success rate. 
Secondary phacoemulsification with IOL implantation surgery has adverse effects on the pre-
existing filteration bleb.Studies have shown that cataract surgery after a glaucoma surgery 
can lead to bleb failure in 30-40% cases
 
(66-68). It increases post-operative IOP, alters the 
bleb morphology and increases the need for anti glaucoma medications
 
(69-72). 
 
Studies have shown IOP spike in two third patients undergoing cataract surgery with pre 
existing glaucoma as compared to 10% in controls
 
(73). One study demonstrated 2.5 times 
increase in IOP after cataract surgery alone than combined surgery
 
(74). 
 
Phacoemulsification with IOL implantation combined with trabeculectomy is associated with 
significant lowering of IOP and number of antiglaucoma medications
 
(75). 
 
Studies have proven that phacoemulsification with IOL implantation combined with 
trabeculectomy is superior to extracapsular catarct extraction (ECCE) with IOL combined 
with trabeculectomy. The former resulted in lower IOP, lesser complications and better bleb 
morphology
 
(76-80). 
 
There are two options for combined phacoemulsification and trabeculectomy surgery. It can 
either be a single site or double site surgery depending on the site for trabeculectomy and 
corneal entry wound. Various studies have shown that both the surgical approaches are 
equally effective in lowering IOP
 
(81-87). 
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ANTIFIBROTICS  
 
Glaucoma surgery is unique in the fact that incomplete wound healing is a desirable outcome. 
A completely healed filtering bleb results in failure.  Wound healing process involves mainly 
two procedures: replacement and regeneration. The former involves formation of scar tissue 
to replace the original tissue while the latter means regeneration of the original tissue without 
any signs of the insult.  
 
Wound healing can be divided into four different phases: 
1. Clot phase 
2. Proliferative phase 
3. Granulation phase 
4. Collagen phase 
 
After any injury like surgical trauma a cascade of events is started which includes 
inflammation and clotting, which results in release of multiple cellular, hormonal and growth 
factors. These factors lead to migration of neutophils, monocytes, macrophages and 
fibroblasts. Fibroblasts produce collagen, elastin and mucopolysaccarides, which lead to 
formation of scar tissue.  
 
The most common cause of failure of filtering surgery is scarring of the bleb. This scarring 
can occur either between the conjunctiva and episclera or between the sclera flap and the 
underlying tissues. It is caused by proliferation, migration and contraction of the fibroblasts.  
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This wound healing response can be altered by interfering at any one of the steps described 
above. 
 
Various adjunctive agents have been described to improve the success rate of the glaucoma 
surgery. The most important among these agents are corticosteroids, 5-FU and MMC. 
 
Corticosteroids act as anti-inflammatory and immunomodulatory agents. They inhibit release 
of inflammatory mediators, growth factors and prevent phagocytosis. This eventually 
decreases the fibroblastic activity and hence wound healing. The use of topical steroids in the 
post operative period is justified but studies have shown that systemic steroids do not have 
any additional advantage
 
(88, 89). 
 
5-FU and MMC were introduced as adjunctive agents in trabeculectomy to enhance the rate 
of surgical success
 
(90-93). However their use is associated with more post-operative 
complications including sight threatening consequences like bleb leak, hypotonic 
maculopathy and endophthalmitis (3-5). 
 
5-FU is a chemotherapeutic agent which undergoes metaoblic transformation and binds to 
thymidylate synthetase. It is a pyrimidine analogue and an antimetabolite. It inhibits DNA 
synthesis and causes cell death. It can also get incorporated into m RNA and hence inhibit 
protein synthesis.It can either be used intraoperatively or in postoperative period. 
Intraoperatively sponges soaked in 25-50 mg/ml of 5- FU is applied at the surgical site for 5 
minutes (94-98). 
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Post operatively 5FU can be used as subconjunctival injections .Some studies have advocated 
daily administration of 5 mg of 5-FU from 7 to 14 days
 
(99-101).Few recommend its use 
from first postoperative day. Success has been reported with its use from 3 to 15 days 
whenever signs of impending bleb failure are noticed
 
(102, 103). Various studies have been 
done to evaluate the intra-operative and postoperative use if injection 5-FU. These are shown 
in table 4 and 5 below.  
 
Table 4: Summary of studies using postoperative 5-FU 
 
Authors Study design Number 
of eyes 
Dose  Outcome 
(study versus 
controls) 
Heuer et al., 
(104)
 
 
Pilot study, complicated 
glaucomas, historical 
controls 
104 3 mg or 5 mg 
injections, 105 mg 
over 2 weeks 
69% vs 39% 
FFSS group.,  
(105)
 
 
Prospective, randomized 
study, in patients with history 
of cataract surgery or failed 
filter 
213 5 mg injections, 105 
mg over 2 weeks 
49% vs 26%  
Araie et al., 
(106) 
Prospective, non-randomized 
mixed, POAG, secondary 
and refractory glaucoma 
362 Mean dose, 36.8 mg in 
POAG group, 49.5 mg 
in secondary 
glaucoma, 36.5 mg  in 
refractory group 
 IOP < 16 mm 
Hg 55.2% vs 
0%  
Goldenfeld 
et al., (107) 
Prospective, randomized 
study in primary 
trabeculectomy 
62 5 mg injections, 5 
injections between day 
1 and day 15 
IOP < 20 mm 
Hg in 94% vs 
73%  
Ophir et al., 
(108) 
Prospective, randomized 
study in primary 
trabeculectomy 
41 4–6 5 mg injections IOP < 20 mm 
Hg in 96% vs 
76%  
Ren et al., 
(109) 
Prospective, randomized 
study in patients undergoing 
combined 
phacotrabeculectomy 
74 5 mg injections over 
first 2 postoperative 
weeks 
No difference 
in two groups 
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Table 5: Summary of studies using intraoperative 5-FU with or without postoperative  
5-FU 
 
 
Authors  Study design(no. of 
eyes) 
Dose 
(application for 
5 minutes) 
Post op 
5FU 
Outcome  
Dietze et 
al.,(110)
 
 
Consecutive case series  
(20) 
50 mg/cc sponge  No  84% had IOP < 21 
reduction of at least 
20% at 3 months 
Anand et 
al.,(111) 
Prospective, non-
randomized study 
(76) 
25 mg/cc sponge  No  84% had IOP < 21 
reduction of atleast 
20% at 3 months 
Mora et 
al.,(112)
 
 
Restrospective study 
(140) 
50 mg/cc sponge Yes  Mean IOP in high-risk 
patients not receiving 
post-op 5-FU was 
15.3mmHg 
Mean IOP in low-risk 
eyes receiving post-op 
5-FU was 10.8 mm Hg 
Towler et 
al., (113) 
Restrospective study 
(50) 
25 mg/cc sponge Yes  IOP < 20 mm Hg in 
82% at 1 and 2 years 
and 67% at 5 years 
 
Experimental studies in rabbits have shown that 5-FU decreases the mitosis and 
differentiation of corneal epithelium as compared to controls. (114) 
 
5-FU is toxic to actively replicating cells like corneal epithelium. It presents as punctate 
keratopathy, filamentry keratopathy, epithelial defects, whorl like or striate melanokeratosis. 
It can lead to secondary complications like corneal ulceration, corneal melt and perforation. It 
is also associated with complications like conjunctival wound leaks in early postoperative 
period and late onset bleb leakage (115-116). 
 
MMC is an antibiotic derived from fungus - Streptomyces caespitosus. It is a cell cycle non 
specific alkylating agent which cross links DNA and thus inhibits DNA replication, mitosis 
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and protein synthesis. Its use as an adjunct to lower IOP in trabeculectomy was first described 
by Chen in 1983
 
(117). 
 
MMC has shown to decrease the proliferation of fibroblasts in tissue culture studies of tenons 
capsule fibroblasts and this correlates with the outcome of filtering surgery
72-73
.(118-119) 
MMC has shown to enhance the success of trabeculectomy in uveitic glaucoma, congenital 
and developmental glaucoma, normal tension glaucoma, refractory glaucoma in black 
patients and primary uncomplicated trabeculectomy
 
(120-126). 
 
Since the outcome of combined cataract and glaucoma surgery may not be as favourable as 
glaucoma surgery alone, the use of antifibrotics is justified in combined surgery (127). MMC 
has been demonstrated to have additional advantage in combined surgery by lowering IOP, 
eliminating the need for additional antiglaucoma medications and formation of larger filtering 
blebs (128-129). Various studies have been done to evaluate the efficacy of these agents. This 
is shown in table 6 below. 
 
Table 6: Summary of studies comparing intraoperative MMC versus 5-FU in combined 
procedures 
Authors No.  of 
eyes 
Study Design Outcome  
Cohen et al., (130) 72 Prospective, double masked, 
placebo controlled 
IOP lower at all time points, 
more early bleb leaks in MMC 
Budenz et al., (131) 78 Retrospective  IOP significantly lower from 
preop in all groups, MMC 
group < than 5FU but not 
lower than no antifibrotic 
Carlson et al., (132) 29 Prospective, randomized placebo 
controlled 
3.0 mm Hg greater mean IOP 
reduction in MMC group 
Shin et al., (133) 197 Prospective, randomized placebo 
controlled 
No overall difference 
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MMC is more potent than 5-FU and hence may also have prolonged cytological toxicity. 
Experiments on cultured mouse fibroblasts and bovine vascular endothelial cells have shown 
that 5-FU is toxic only to the former while MMC is toxic to both the cell types
 
(134-135). 
 
MMC can lead to formation of thin walled avascular blebs and late onset bleb leaks. This is 
three times more common with MMC than 5-FU (136). This may ultimately result in 
endophthalmitis. Such avascular thin blebs lead to overfiltration and subsequent hypotony. 
The consequences of hypotony include choroidal detachment, shallow anterior chamber, 
corneal decompensation. The term hypotonic maculopathy was coined by Gass in 1972. The 
entity includes disc edema, vascular tortuosity and macular chorioretinal folds leading to 
decrease in visual acuity. He proposed that it was caused due to contraction of the elastic 
sclera leading to chorioretinal folds
 
(137). 
 
The mechanism for hypotony is overfilteration which has been supported by histological 
studies of excised blebs which showed irregular epithelium and acellular subepithelium of 
loose connective tissue
 
(138-140). Another proposed mechanism is aqueous hyposecretion. 
Enucleated human eye showed disruption of ciliary body epithelium at the site of application 
of MMC. Monkey and rabbit eyes showed suppression of aqueous flow
 
(141-143). Early 
postoperative hypotony can later lead to failure of the bleb. Hypotony results in formation of 
secondary aqueous which contains factors which increases wound healing and hence scarring 
around the sclerostomy site (144). 
 
Zacharia et al in a retrospective study found incidence of hypotony of 1 in 3(defined as IOP < 
5mm Hg). 0.4 mg MMC was used for duration of 3.5 to 7 minutes in 52 eyes of 48 patients.7 
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eyes required surgical intervention for hypotony. They also found that longer time of 
application increased the chances of hypotony (145). 
 
In a case series of 10 patients MMC was used after pterygium surgery. It was associated with 
side effects like scleral and corneal melt, corneal edema, scleral calcification, iritis, 
corectopia (146).
 
MMC is also associated with endothelial toxicity. A study demonstrated that 
MMC caused 10-11% more loss of endothelium as compared to controls
 
(147). 
 
Different studies have demonstrated that MMC use is associated with higher rate of 
endophthlamitis
 
(148-152).  Greenfeld et al.,
 
(148) did a retrospective analysis and followed 
609 eyes and followed them for 3 months. Bleb associated endophthalmitis developed in 
2.1% patients and the most common organisms isolated were Streptococcus sanguis and 
Haemophilus influenza. The rate of endophthalmitis was 13% and 1.6% for the inferior and 
superior blebs respectively. However it also included inferior trabeculectomy.  
 
A retrospective study by Peter de et al
 
(150) was done on 239 eyes of patients undergoing 
trabeculectomy with MMC with a follow up of 7 years.0.5 mg/ml MMC was used for 30 
seconds to 5 minutes in different patients. The complications of bleb leak, blebitis and 
endophthalmitis were seen in 20 eyes (8%), 5 eyes (2%) and 8 eyes (3%) respectively.5 year 
probability of bleb leak, blebitis and endophthalmitis was calculated to be 17.9%, 6.3%, 7.5% 
respectively by Kaplan meier analysis.  
 
Another retrospective case series by Rajiv Bindish et al., (153) was done on 123 eyes of 
patients undergoing primary trabeculectomy with MMC with a follow up of 4 years. Weck-
cell soaked sponge of MMC 0.25, 0.33, 0.5 mg/ml was used for 0.5 to 5 minutes duration.  
- 36 - 
 
The complications of hypotony, hypotonic maculopathy, bleb leak, blebitis, endophthalmitis 
was seen 42.2%, 8.9 %, 14.6%, 5.7 %, 0.8% of eyes respectively. These complications were 
seen at a mean follow up of 26.1 months, 33.7 months, 27.9 months, 35.4 months, 15 months 
respectively. 
 
A retrospective analysis of 632 patients was done by Kiyofumi et al., (154) trabeculectomies 
were performed with or without MMC or 5FU. At a mean follow up of 3.5 years, bleb related 
infection was seen in 1.3%, 1.3%, 1.1 % of cases without any antifibrotic agent, with 5-FU 
and with MMC respectively. All the cases that developed infection were associated with 
avascular or hypovascular cystic blebs and low IOP. There was no difference in the incidence 
of bleb related infection in the three groups
110
.  
 
A retrospective analysis
111
 of 609 eyes was done by David et al., (155). These patients 
underwent trabeculectomies in conjunction with MMC. Average follow up was 16.0+/-11.5 
months. 13 eyes developed endophthalmitis (2.1%). It was more common with inferior 
trabeculectomies than superior trabeculectomies (7.8% per patient-year vs 1.3% per patient-
year). Cumulative incidence was 13% and 1.6% respectively for inferior and superior blebs. 
The rate of endophthlamitis in trabeculectomies without antifibrotics has been reported to be 
0.2-1.5%. 
 
A retrospective analysis was done by Takashi et al., (156). The study included 123 eyes which 
underwent trabeculectomy with MMC. 0.4 mg/ml MMC was used for 3 minutes. At the end 
of 8 years follow up bleb leak, hypotonic maculopathy, bleb related infection was seen in 7.9 
%, 8.3 %, 5.9 % cases respectively. 
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Different protocols for MMC application have been described but there is no optimum 
protocol established. In early protocols 0.5mg/ml of MMC was applied for 5 minutes. Some 
retrospective studies advocate application of .02% MMC for 2 minutes (157). It is adviced to 
assess each patient and the associated risk factors individually and hence determine the 
dosage accordingly. Table 7 describes various studies comparing MMC and 5-FU in 
trabeculectomy. 
 
Table 7: Summary of the studies comparing MMC and 5-FU in trabeculectomy 
 
Author  No. of 
eyes 
Dose  Follow up 
in months 
Outcome ( MMC 
versus 5FU) 
Lamping and 
Belkin (158) 
80 Adjunctive MMC versus 5 FU 12 Mean IOP: 12.8 vs 
14.8 (p=0.001) 
Smith et al., 
(159) 
73 MMC 0.2 mg/ml for 3–5 minutes or 
5-FU 50 mg/ml for 5 minutes 
20.9 Mean IOP: 10.2vs 9.7 
(p<0.001) 
Singh et al., 
 
(160) 
108 MMC 0.4 mg/cc for 2 minutes with  
5-FU 50 mg/cc for 5 minutes 
10-11  No difference  
 
Other antifibrotics which have been evaluated includes cytosine arabinoside, bleomycin, 
rapamycin, doxorubicin, daunorubicin, 5-fluoroorotate, heparin, taxol, cytochalasin-B, 
colchicine, immunotoxins, Suramin and interferon α2b. 
 
Suramin is a growth factor inhibitor. It’s efficacy has been studied in rabbits (161) and 
humans (162). In a prospective study (162) Suramin was found to have success rates 
comparable to MMC and complications less than MMC. 
 
β irradiation can delay healing of wound which has been demonstrated in rabbit studies (163). 
Also tissue culture experiments have shown inhibition of fibroblast growth by β irradiation. 
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Study by Miller et al., (164) in patients with congenital glaucoma demonstrated beneficial 
effect of β irradiation on trabeculectomy. 
 
Other alternatives of MMC tried are amniotic membrane transplant (165) and subconjuntival 
perfluoropropane (166-167). 
 
Agents which alter other phases of the wound healing have also been evaluated. For example, 
tissue plasminogen activator, which causes localized fibrinolysis, ¥interferon and calcium 
ionophores, which inhibit collagen biosynthesis and D-penicillamine, which inhibit cross-
linking of collagen, have shown promise in in vitro and in vivo studies (168-169).  
 
Various biodegradable implants have been tried in glaucoma surgeries. A polyfilm (L 
lactideco- epsilon-caprolactone) has been shown to be superior to controls in lowering IOP 
and equally efficacious to MMC in rabbit eyes
 
(170). It is a 7µm thick implant which has two 
surfaces. The surface with a honeycomb pattern is placed facing the tenon’s capsule and the 
other surface which is smooth faces towards the sclera. The honeycombed surface acts as a 
barrier for formation of fibrous scar tissue and inhibits inflammation. 
 
Two other implants: seprafilm (sodium hyaluronate and carboxymethylcellulose) and 
hyaluronic acid–carboxymethyl cellulose film have been shown to reduce postoperative 
scarring in glaucoma surgeries
 
(171-172). In a study by Tsurumaru et al., (171) in rabbits IOP 
was significantly lower in cases than controls (p= .0044) at 28 days follow up. Histological 
analysis showed lesser adhesions between the sclera and the conjunctiva in the cases than the 
controls (p=0.0041). 
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OLOGEN 
Ologen (Aeon Astron Europe BV, Leiden, the Netherlands) is a porcine derived 
biodegradable implant. It is a three dimensional polymer made up of lyophilized collagen 
(>90%) and glycosaminoglycan (<10%). It causes wound healing by a non scarring process 
without using anti-fibrotic agents. It induces the conjunctival fibroblasts and myofibroblasts 
to grow randomly within its porous structure and secrete a loose connective tissue matrix. It 
thus creates a new physiologic environment in the filtering bleb reducing wound contraction. 
It acts like a reservoir, a buffering system and maintains a controlled drainage of aqueous. It 
induces a regenerative non scarring process of wound healing. It is the first application of 
bioengineering to glaucoma. Animal studies have shown it to be effective in glaucoma 
filtering surgery
 
(173-174). 
 
The pore diameter varies from 10-300 um. There are various models depending on the 
dimensions of the implant as shown in table 8 below. 
 
Table 8: Dimensions of the different models of Ologen  
Model  Height (mm) Diameter (mm) 
830601 2.0 6.0 
830661 4.0 7.0 
830681 4.5 7.5 
830691 5.0 10 
862051 1.0 12.0 
 
There is a newer version of Ologen implant, named as version 2. It is made up of 
atelocollagen. Structure of the collagen molecule consists of aminoacid sequence known as 
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telopeptide at the C and N terminal. It confers immunogenicity to the collagen molecule. 
Atellocollagen is obtained by treatment with pepsin and is free of telopeptides. Therefore it 
has lower immunogenicity.  It is said to have additional anti-inflammatory action in the 
surrounding tissue
 
(173). 
 
Non ophthalmological uses of atelocollagen include intradermal injection in plastic surgery, 
as a substitute of bone cartilage, wound healing. This version has been used in our study- 
830601 with dimensions of 2 x 6 mm. 
 
The implantation is a simple procedure and requires minimal modification during the surgery. 
It is placed over the sclera flap before closing the conjunctiva and tenon’s capsule in a water 
tight fashion. Animal studies have shown that the implant completely degrades in 30-60 days
 
(174). 
 
It does not cause complications associated with antifibrotic agents like ocular surface toxicity, 
endothelial toxicity, wound leak, hypotony, hypotonic maculopathy, blebitis, endophthalmitis. 
Also MMC is teratogenic, increases the operating time and has specific disposal 
requirements. Ologen does not have any such disadvantages. It applies a dynamic pressure 
over the sclera flap and hence maintains a dynamic fluid control and prevents hypotony. 
However the cost is Rupees 4,700 which limits its routine use in developing countries like 
ours. 
Indications for use of Ologen: 
1. Failed Trabeculectomy 
2. Primary Trabeculectomy (combined and sequential ) 
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3. Pterygium Surgery 
4. Strabismus surgery 
5. Ocular surface reconstruction 
6. Sub conjunctival scar revision 
 
STUDIES COMPARING MMC AND OLOGEN IMPLANT 
 
Since the introduction of Ologen implant, various studies have been done to evaluate its 
efficacy in different types of glaucoma surgeries.  There are four studies comparing Ologen 
with MMC. There are three Randomized Controlled Trials (RCTs) comparing MMC and 
Ologen implant in trabeculectomy. One study by Boey et al
 
(9) studies compared the two 
agents in phacotrabeculectomy surgery. Table 9 summarizes these studies: 
 
Table 9: Summary of studies comparing MMC versus Ologen  
Author Study type Follow 
up 
period 
Total 
no. of 
patients 
Type of surgery Ologen 
model 
MMC  Results P 
value 
Marey et 
al., (6) 
RCT 1 year 60 (30 
in 
each) 
Trabeculectomy  830601 0.2mg/ml 
for 2 min 
MMC and 
Ologen 
equally 
efficacious 
0.581 
Boey et al., 
(9) 
Prospective 
interventional 
case control 
study 
3 
months 
66 (33 
in 
each) 
Phaco 
trabeculectomy 
83068 0.4 
mg/ml 
for 2 min 
IOP 
control 
better in 
MMC 
than 
Ologen 
<0.001 
Rosentreter 
et al., (8) 
RCT 1 year 20 (10 
in 
each) 
Trabeculectomy Version1 
(model no. 
not 
mentioned)  
0.2 mg/ 
ml for 3 
min 
IOP 
control 
better in 
MMC 
than 
Ologen 
0.01 
Cillino et 
al., (7) 
RCT 2 years 40 ( 20 
in 
each) 
Trabeculectomy 830601 0.2mg/ml 
for 2 min 
MMC and 
Ologen 
equally 
efficacious 
0.92 
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RCT done by Marey et l., (6)included 60 patients with the diagnosis of POAG, CACG, PEX 
Glaucoma, uveitic glaucoma and pseuodphakic glaucoma. They used 0.2mg/ml MMC for 2 
minutes and Ologen model 830601. Absolute success was defined as IOP < 21 mm Hg 
without any topical medications. At the end of 1 year there was no significant difference in 
IOP (p value=0.581) and complication rate (p value=0.678) in between the two groups. Bleb 
morphology was studied using Moorfields bleb grading system. No statistically significant 
difference was seen in the bleb area and height score. Bleb vascularity score was higher in the 
MMC group (p value= 0.001). 
 
A prospective interventional case control study was done by Boey et al., (9) to compare 
phacotrabeculectomy with ologen implant versus MMC. It included 33 patients diagnosed to 
have POAG and PACG in each group. Patients underwent two site phacotrabeculectomy. In 
the MMC subgroup 0.4 mg/ml MMC was applied for 2 minutes duration.  Patients were 
followed for a period of 3 months. Mean reduction of IOP was greater in the MMC group (p 
value < 0.001). Bleb morphology was evaluated using Moorfields bleb grading system at the 
end of 60 days. Bleb vascularity score was higher and bleb height, lower in the ologen group. 
The bleb height in ologen group was mainly because of the implant while in the MMC group 
it was due to the aqueous lake in the bleb. Anterior Segment OCT showed retained ologen 
implant in 39.4 % cases at the end of 3 month follow up.  
 
RCT was done in Germany by Rosentreter et al., (8). It compared Ologen and MMC in 
trabeculectomy. It was done in patients diagnosed with open angle glaucoma with a follow up 
of 1 year. 20 patients were randomized to either MMC or Ologen group. In the former group 
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0.2mg/ml MMC was applied for 3 minutes after making a fornix based conjunctival flap. In 
the latter group version 1 of Ologen implant was placed over the sclera flap before closing the 
conjunctiva. One difference in the suturing technique in Ologen group was that a loose scleral 
flap suture was placed in place of tight suture in MMC group. Complete success was defined 
as IOP </= 18 mmHg or 20 % reduction in IOP without any antigaucoma medications or any 
additional surgery. After 1 month of follow up onwards significant IOP difference was seen in 
both the groups, with IOP being lower in the MMC group. Complete success was achieved in 
100 % patients in MMC group while only 50% patients achieved complete success in the 
ologen group (p value =0.01). No significant difference was seen in the rate of complications 
in both the groups. Early hypotony was common in the ologen group which may be attributed 
to loose suturing of the sclera flap in this group. Morphology of the bleb was studied using 
Wuzberg Classification system. In the MMC group blebs were more prominent, more 
avascular with more microcysts, while in the ologen group blebs were more flat, diffuse and 
vascular. One patient in mitomycin group developed vascular bleb with leak at 3 month 
follow up and required revision surgery. Ologen implant was not visualized in any patient by 
ultrasouind biomicroscopy at the end of 1 month. 
 
Another RCT was done in Italy
 
by Cillino et al., (7). It included 40 patients of POAG/PEX 
Glaucoma and they were followed for a period of 24 months. MMC was used at a 
concentration of 0.2 mg/ml and applied for duration of 2 minutes. As in the above mentioned 
study ologen implant was placed over the sclera flap after suturing it with a loose suture. 
Target IOP was divided into three subgroups: </=21 mm Hg, </=17 mm Hg and </=15 mm 
Hg. Complete success was defined as achieving the target IOP without any medications or 
additional surgery. There was no significant difference in the success rate between the two 
groups (p value=1.0; 1.0; 0.75 in each target group respectively). Also there was no 
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statistically significant difference in the complication rates between the two groups. Bleb 
evaluation was done using Moorfields Bleb Grading System and Spectral domain OCT. Bleb 
height was higher in the ologen group as compared to the MMC group. But there was no 
difference in the bleb area and vascularity score between the two groups.  
 
A randomized clinical trial
125
 was done by Dimitris et al., (175) in Greece. It compared 
trabeculectomy with and without Ologen implant. 40 patients were randomized and followed 
for 6 months period. There was no additional benefit seen in patients who underwent 
trabeculectomy with Ologen implant (p value=0.985). Though there was no statistically 
significant difference between the two groups in complications, one patient developed 
endophthlamitis and two other patients developed shallow anterior chamber secondary to leak 
and required resuturing in the Ologen group.  
 
Version 2 of Ologen implant was used in a study done by Rosentreter et al., (176); evaluating 
its efficacy in revision surgery after failed glaucoma drainage surgery. It was an observational 
comparative case series. 10 patients underwent revision surgery with Ologen implant and 
MMC while 9 patients were retrospectively observed who underwent capsule excision with 
MMC alone. The success rate was significantly better in the Ologen group (p value=0.04).  
Aptel et al.,
 
(177) studied the efficacy of Ologen implant in deep sclerectomy surgery. It was 
a case series of 15 patients with POAG There was a significant reduction of IOP (p value= 
<.001) at the end of three month follow up visit. 
 
There are no randomized controlled studies in Indian eyes comparing MMC and Ologen in 
either trabeculectomy or phacotrabeculectomy. There is only one study by Tanuj Dada et al., 
(10) done in Dr. Rajendra Prasad Eye Institute, New Delhi. It was a retrospective study which 
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included 33 eyes of 24 patients who underwent trabeculectomy with Ologen and MMC- 
0.1mg/ml for duration of 1 minute. At the end of 12 months follow up period IOP was 
significantly lower in the Ologen with MMC group than the control (p value < 0.001).  
Different races respond differently to wound healing after any glaucoma surgery. So we need 
more Indian studies to evaluate the efficacy of Ologen implant. 
 
Out of the 3 randomized control trial comparing MMC and Ologen, the study done by 
Rosentreter et al., (8)demonstrated MMC to be superior to Ologen implant whereas study by 
Cillino et l., (7) and Marey et al., (6)showed Ologen to be as efficacious as MMC in control 
of IOP. The case control study by Boey et al., (9) in phacotrabeculectomy also showed MMC 
to be superior to Ologen. Also the randomized control trial comparing Ologen to placebo by 
Dimitris et al., (175) showed no benefit of Ologen implant over trabeculectomy without 
implant. Version 2 of Ologen implant was used by Cillino et al., (7), Marey et al., (6)and 
Rosentereter et al., (8). The observational comparative case series by Rosentreter et al., (8) 
evaluated efficacy of Ologen and MMC versus MMC alone in the revision surgery done after 
failed glaucoma drainage device surgery. This study demonstrated the former to be better than 
the latter. More studies, specially randomized controlled trials are needed to evaluate its 
efficacy. 
 
None of these studies have studied the role of post operative use of 5-FU along with Ologen. 
Postoperatively in vascular blebs, subconjunctival 5-FU injections can help decrease the 
vascularity and improve the success rate of trabeculectomy surgery. 
 
Therefore a randomized control study is required which can compare MMC and Ologen 
implant (version 2) in Indian eyes in conjunction with post-operative 5-FU.  
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BLEB GRADING SYSTEMS 
Morphology of bleb is an indicator of bleb function and can predict long term success and 
bleb related complications
 
(178-180). There are various classification systems for bleb 
morphology. 
 
Moorfield’s bleb grading system (181) is one of them which assess bleb area, height and 
vascularity. It is a system of grading in which photographs of the bleb area is compared to a 
standard photograph. Photograph is taken with eye looking down with maximum part of 
superior conjunctiva visible. The canthal margins are the horizontal limits of the photograph. 
Grading is then done with the photographs magnified to a diagonal length of 15 inches. They 
are compared to a standard set of photographs. Bleb is graded to the best possible match out 
of the set of standard photographs as shown in Appendix G. 
 
Three aspects are evaluated- bleb area, height and vascularity. There are six criteria to be 
assessed- 2 describing area, 1 for height and 3 for vascularity.  
 
1. Area: It is divided into a central demarcated area and peripheral margins. It is graded 
in relation to the total superior conjunctiva visible. 
 
 1a. It is the bleb area above the sclera trap door. If not visible then it is graded same as 
the peripheral area. It is graded depending on the extension. 
       1= 0 % 
       2= 25 % 
       3= 50 % 
       4= 75 % 
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       5= 100 % 
 
      2a. It is the total area of the bleb in comparison to the total superior conjunctiva 
visible. It is similarly graded depending on the extension: 
       1= 0 % 
       2= 25 % 
       3= 50 % 
       4= 75 % 
       5= 100 % 
 
2. Height:  Score is given after comparing it to a standard reference photograph. It is 
given a score of 1-4 with increasing height. This is applied to the highest point on the 
bleb, usually at its centre. 
 
3. Vascularity: It is subdivided into three different areas: 
 
3a. It refers to the central demarcated area of the bleb as described in 1a  
3b. It refers to the bleb area as described in 1b. When there is no peripheral part as in 
an encysted bleb, the margin between the central area and the non bleb conjunctiva 
should be described. 
3c. It refers to the peripheral non bleb conjunctiva. If the bleb area is 100 % then it 
should be graded same as 3b.  
Then each area is compared to a standard photograph and graded as follows: 
1- Avascular 
2- Normal vascularisation 
3- Mild vascular inflammation 
4- Moderate vascular inflammation 
5- Severe vascular inflammation 
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Subconjunctival hemorrhage is noted as follows: 
           Yes- If subconjunctival blood is more than the scleral trap door. 
            No- If subconjunctival blood is less than the scleral trap door or absent. 
 
Wurzburg classification
 
(182-184) evaluates three parameters of bleb morphology which 
are avascualrity, corkscrew vessels and microcysts. 
 
Avascularity and corkscrew vessels are scored from 0-3 as follows: 
0- Entire bleb 
1- 2/3 rd of bleb 
2- 1/3 rd of bleb 
3- None  
Microcysts are classified from 0-3 as follows: 
0- None  
1- Over the sclera flap 
2- Lateral and medial to the sclera flap 
3- Entire bleb  
 
Indiana bleb appearance grading scale: (185) This grading system is comparing four 
different parameters of bleb morphology with standard photographs. It includes- 
1- Standards for bleb height 
2- Standards for extent 
3- Standards for vascularity   
4- Standards for seidel’s test  
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MATERIALS AND METHODS 
Study design:  
Randomized, parallel group, active controlled trial 
 
Sample size calculation:  
The sample size was calculated based on a previous study by Rosentreter et al., (8) which 
compared MMC versus Ologen in trabeculectomy. The primary outcome of this study was 
reduction in IOP. From the previous study, we found that the mean reduction in IOP in the 
MMC group was 11.5mm Hg (SD= 4.1mmHg) and in the Ologen was 15.6 mm Hg (SD= 
2.4mm Hg). To estimate a difference of 4 mmHg with a power of 80% and 5% level of 
significance, we calculated a total sample size of 60 (30 in each group). Considering lost to 
follow up rate of 5%, a sample size of 63 patients was obtained.  
 
Setting:  
This was a randomized controlled trial conducted from December 2011 to November 2012. 
The study was conducted in the Department of Ophthalmology, Christian Medical College, 
Vellore. 
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Inclusion criteria: 
Patients attending the general outpatient department and the glaucoma clinic  who required 
treatment with standard phacotrabeculectomy as decided on clinical evaluation by the 
glaucoma specialists were invited for the study. It included patients with: 
 POAG 
 PEX Glaucoma 
 Pigmentary Glaucoma 
 Steroid induced glaucoma 
 Angle Closure Glaucoma 
 NTG 
 OHT 
 Subject able and willing to cooperate with investigation plan. 
 Subject able and willing to complete postoperative follow-up requirements. 
 Subject willing to sign informed consent form.  
Exclusion criteria: 
 Ocular infection within 14 days prior to surgery. 
 Glaucoma types which are more amenable to undergo primary valve repair will 
not be included. It includes:  
 NVG 
 Uveitic glaucoma 
 Pupillary block glaucoma secondary to subluxated lens 
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 Previous ocular surgery. 
Patients fulfilling the above inclusion and exclusion criterion and willing to participate in the 
study by signing the consent (Appendix C, E- Consent in English and Tamil) were recruited 
into the study. 
Institutional Review Board approval 
The study protocol was approved by the Institutional Review Board which constituted 
members outside the institution as per the ICMR guidelines required for any study conducted 
in the institution. (Appendix A- IRB approval) 
Method of randomization:  
Block randomization technique with variable block sizes of 4, 6 and 8. 
 
Method of allocation concealment: 
 Opaque sealed envelopes were used to conceal the sequence of random allocation. The 
envelopes were opened after recruitment of the participant into the study. 
 
Preoperative examination: 
After relevant history including the use of antiglaucoma medications, each patient underwent 
comprehensive eye examination by slit lamp biomicroscopy and indirect ophthalmoscopy 
which included:  
 Best Corrected Visual Acuity using Snellen’s visual acuity chart 
 Anterior chamber depth by Von Herrings test 
 Pupillary reaction to assess Relative Afferent Pupillary Defect 
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 Recording IOP by Goldmann applanation tonometer on atleast two different occasions 
 Gonioscopy by Goldmann 2 mirror or Sussmann 4 mirror 
 Fundus examination by 78 D lens and disc size assessment using a correction factor of 
1.1 
 Central corneal thickness(CCT) measurement using ultrasound pachymetry 
 Standard automated perimetry (Humphrey Visual Field Analyser) using 24-2 or 30-2 
SITA Standard protocol and 10-2 and macular program where indicated 
 
Target IOP: 
Prior to randomization of the patient, the target IOP was decided by the operating surgeon  
based on the extent  of glaucomatous disc changes, severity of field defects, baseline IOP , 
age of the patient and the CCT. 
 
Definition of success: 
IOP within + 2mm Hg of target IOP  
 
Definition of failure: 
IOP more than +2 mmHg of target IOP and /or IOP ≤ 6 mm Hg (hypotony and hence defined 
as failure)  
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Technique of surgery: 
All patients underwent two site combined trabeculectomy and phacoemulsification surgery 
with implantation of foldable intraocular lens under peribulbar anesthesia. The surgery was 
performed by one of four glaucoma specialists according to the standard surgical technique as 
described below. MMC or Ologen was used as per the randomization. MMC was used in a 
concentration of 0.4 mg/ml and Ologen implant model 83601 was used. 
 
 Steps of surgery are described as shown below: 
 Dressing and draping was done to ensure sterility of the operating field and superior 
rectus bridle suture applied. 
 Superior fornix based conjunctival peritomy was done using blunt tipped Westcott 
scissors.  
 Cauterization was done meticulously by monopolar cautery. 
 In the MMC group, after peritomy 3 sponges soaked in 0.4mg/ml of MMC was placed 
under the conjunctiva for duration of 90 seconds. It was then thoroughly irrigated with 
balanced salt solution.  
 A rectangular partial thickness sclera flap (2/3rd depth of scleral thickness) was made. 
 Using a clear corneal incision at a separate site, cataract extraction was done by 
routine phacoemulsification with foldable Intraocular lens implantation. 
 Pupil was constricted with intracameral pilocarpine if required. 
 Under the scleral flap, the trabecular block excision was done using superblade and 
angled Vann’s  scissors or a Kelly Descemet’s  punch. 
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 Peripheral iridectomy was done by grasping the iris tissue through the trabecular 
block and excising it with Vanna’s scissors keeping it parallel to the limbus. 
 1 releaseable suture and one fixed sclera flap suture were placed at the upper corners 
of the rectangular scleral flap. 
 In patients randomized to Ologen, the Ologen implant was placed such that the 
anterior end of the implant rested at the posterior border of the rectangular scleral 
flap. 
  The conjunctiva was closed with wing sutures and one  mattress suture. 
 
Follow up:  
All patients were followed up as per schedule shown below:  
 Day 1 
 Week 1 ± 3 days 
 6 Week ± 5days  
 3 Month ± 1 week 
 
Most patients were discharged from the hospital on the fifth post-operative day. The 
examination during each follow up included: 
 
 Best Corrected Visual Acuity by Snellens chart 
 Bleb morphology assessment and grading by Moorfields grading system as described 
in Review of literature. 
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 Seidel’s test 
 Anterior chamber depth assessment by Von Herrick’s test 
 IOP by Goldmann applanation tonometer  
 Fundus examination with 78 D/20D indirect ophthlamoscopy  
 Postoperative antiglaucoma medications if needed 
 Postoperative wound modification required was noted: 5FU injections, laser 
suturolysis, bleb massage, releaseable release, needling. Injection 5-FU in a dose of 
5mg in 0.1 ml was given subconjunctivally above the site of bleb to patients if the 
bleb was found to be vascular. Bleb massage was given as and when needed to keep 
the bleb formed. External bleb needling was done if the bleb was encysted / flat due to 
fibrosis. 
 
Statistical analysis:  
 
 
The collected data was compiled on Microsoft Excel Spreadsheet and was analyzed with the aid of 
SPSS data analysis software version 17.0.  
Analysis of the baseline characteristics of each group was done using cross tab tables and the 
significance was determined using Chi square test. 
Success and failure in each group was also compared using Chi square test. All the evaluations were 
done at 6 weeks and 3 months follow up period. The rate of complications, additional interventions, 
bleb morphology characteristics and number of injections of 5-FU were also evaluated using Chi 
square test. The comparison in between the two groups was done by Mann Whitney test. 
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RESULTS 
 
 Patients were recruited and followed up as per the flow chart shown below: 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized to 
each arm 
1 patient lost to follow up 
at 6 weeks 
1 patient lost to follow up 
at 6 weeks 
Phacotrabeculectomy 
 Phacotrabeculectomy 
MMC GROUP 
n=32 
OLOGEN GROUP 
n=31 
Above 1 patient 
continued to be lost to 
follow up 
Total 4 patients lost 
to follow up 
Above + 2 more patients 
lost to follow up 
63 eyes of 63 patients 
n=63 
- 57 - 
 
 
A total number of 63 patients (table 10) were included in the study. They were randomized to 
phacotrabeculectomy with either MMC or Ologen implant.  
 
Table 10: Number of patients in the two groups 
MMC Ologen 
32 31 
 
 The baseline characteristics of the two groups of patients are described under the following 
headings. There was no statistically significant difference in the baseline demographics of the 
patients.  
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1. Gender distribution: Gender distribution in the two groups is shown in table 11 and 
figure 1.  
 
Table 11: Gender distribution in the two groups 
 Male (%) Female (%) Total (%) 
MMC 17(53.13) 15(46.88) 32(100.00) 
Ologen 16(51.61) 15(48.39) 31(100.00) 
Total 33(52.38) 30(47.62) 63(100.00) 
                    
 
 
 
Figure 1: Graph showing the gender distribution in the two groups 
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2. Eye operated: The frequency of the eye operated in the two groups are shown in 
table 12 and figure 2. 
 
Table 12: Frequency of the eye (right/left) operated in the two groups 
 MMC (%) Ologen (%) Total (%) 
Right  17(54.84) 14(45.16) 31(100.00) 
Left 15(46.88) 17(53.13) 32(100.00) 
Total 32(50.79) 31(49.21) 63(100.00) 
                    
 
 
Figure 2: Graph showing the distribution of the eye (right/left) operated in the 
two groups 
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3. Age distribution 
Table 13 and figure 3 show the decade wise age distribution in the two groups. More than 
50% of patients were in the age group 61-70 years. The second most common age group was 
51-60 years.  
 
Table 13: Distribution of patient across different age groups in the two groups 
 MMC (%) Ologen (%) Total (%) 
40-50  2 (6.45) 3(9.37) 5(7.94) 
51-60  6 (19.35) 11(34.37) 17(26.98) 
61-70 19 (61.29) 14(43.75) 33(52.38) 
>70 5 (16.13) 3(9.37) 8(12.70) 
Total 31 32 63 
 
 
Figure 3: Graph showing the age distribution of patients in the two groups. 
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4. Diagnosis  
POAG was the most common diagnosis. The next most common diagnosis was NTG. 
There was no statistically significant difference in between the two groups in the 
distribution of different diagnoses although more patients with NTG were in the 
MMC group. Table 14 and Figures 4, 5, 6 show the distribution of the types of 
glaucoma diagnosed in the two study groups. 
Table 14: Distribution of the various diagnoses in the two groups 
 POAG(%) NTG(%) PACG(%) PEX 
glaucoma(%) 
OHT(%) Total(%) 
MMC 11(34.38) 14(43.75) 3(9.38) 3(9.38) 1(3.13) 32(100.00) 
Ologen 16(51.61) 7(22.58) 3(9.68) 3(9.68) 2(6.45) 31(100.00) 
Total 27(42.86) 21(33.33) 6(9.52) 6(9.52) 3(4.76) 63(100.00) 
 
Figure 4: Pie diagram showing the distribution of the various types of glaucoma 
among the subjects in the MMC group 
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Figure 5: Pie diagram showing the distribution of the various types of glaucoma 
among the subjects in the Ologen group 
 
 
 
 
Figure 6: Pie diagram showing the distribution of the various types of glaucoma 
in the entire study group (MMC and Ologen) group 
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5. Lost to follow up 
At the end of 6 weeks 1 patient was lost to follow up in each group.4 patients were 
lost to follow up at 3 months. Details of the lost to follow up patients are given in 
table 15 and figure 7. 
Table 15: Details of patients lost to follow up at 6 weeks and at 3 months in the 
two groups 
 MMC (%) Ologen (%) Total (%) 
6 weeks 1(3.23) 1(3.12) 2(3.17) 
3 months 1(3.23) 3(9.37) 4(6.35) 
 
 
Figure 7: Graph showing patients lost to follow up in each group 
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6. Preoperative IOP 
There was no statistically significant difference between the preoperative IOP in 
between the two groups (p value=0.06). It is shown in table 16 below. As we saw 
above NTG comprised about 44% patients in MMC group while POAG comprised 
52% patients in Ologen group. Therefore mean IOP was higher in the Ologen group 
but it did not affect the results as success was defined for each case individually based 
on target IOP as detailed  under the  section of  ‘materials and methods’ . 
Table 16: Mean preoperative IOP in the two groups 
MMC (mm Hg)/ Mean±SD Ologen (mm Hg)/ Mean±SD 
20.55 ± 6.42 23.97 ± 10.42 
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7. Number of preoperative medications 
As shown below 58.73% were not on any preoperative medication while 6.35% patients were 
on 3 different subgroups of antiglaucoma medications. The details about the number of 
medications are shown in table 17 and figure 8. There was no statistically significant 
difference between the two groups (p= 0.714). 
 
Table 17: Distribution of patients ‘on’ or ‘not on’ antiglaucoma medications pre-
operatively in the two groups 
 Patients on 
no 
medication 
(%) 
Patients on 
single 
medication 
(%) 
Patients on 
two 
medications 
(%) 
Patients on 
three 
medications 
(%) 
Total 
MMC 18(56.25) 7(21.88) 5(15.63) 2(6.25) 32(100.00) 
Ologen 19(61.29) 8(25.81) 2(6.45) 2(6.45) 31(100.00) 
Total 37(58.73) 15(23.81) 7(11.11) 4(6.35) 63(100.00) 
                          
 
Figure 8: Graph showing preoperative medications in the two groups 
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8. Outcome  at 6 weeks 
80% of the patients in the MMC group achieved target IOP at 6 weeks as compared to 
70% in the Ologen group (0.334). However this difference was not statistically 
significant. The details of the IOP are shown in table 18, 19 and figure 9. 
Table 18: Success and failures in the two groups at 6 weeks 
 Success (%) Failure (%) Total (%) 
MMC 25(80.65) 6(19.35) 31(100.00) 
Ologen 21(70.00) 9(30.00) 30(100.00) 
Total 46(75.41) 15(24.59) 61(100.00) 
  
 
 
 
Figure 9: Graph showing the distribution of success and failure in the two groups at 6 
weeks  
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Table 19: Mean IOP in the study groups at baseline and at 6 weeks 
 MMC (mm Hg) Ologen (mm Hg) 
Baseline IOP  20.55 ± 6.42 23.97 ± 10.42 
6 weeks IOP 11.93 ± 5.20 13.52 ± 4.64 
 
The mean reduction in IOP in MMC group and Ologen group was 8.47 ± 6.77 mm Hg and 
10.33 ±10.86 mm Hg respectively. Both were statistically significant drop from the baseline 
(p<0.001). The reduction in IOP in between the two groups was not statistically significant (p 
= 0.268).  
 
9. Outcome  at 3 months 
By the end of 3 months.87.1% of the patients in the MMC group achieved target IOP 
as compared to 88.14% in the Ologen group (p=0.795). The details of the IOP are 
shown in table 20, 21and figure 10. 
Table 20: Success and failures in the two groups at 3 months 
 Success (%) Failure (%) Total (%) 
MMC  27(87.10) 4(12.90) 31(100.00) 
Ologen  25(89.29) 3(10.71) 28(100.00) 
Total 52(88.14) 7(11.86) 59(100.00) 
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Figure 10: Graph showing the distribution of success and failure in the two groups at 3 
months 
 
 
 
Table 21: Mean IOP in the study groups at baseline and at 3 months 
 MMC(mm Hg)/ Mean ± SD Ologen(mm Hg)/ Mean ± SD 
Baseline 20.55 ± 6.42 23.97 ± 10.42 
3 months 12.39 ± 3.3 13.18 ± 4.3 
 
There was no statistically significant difference in the mean postoperative IOP (p value = 
0.47). The mean reduction of IOP from baseline to 3 months was 8 ± 6.5 mm Hg in MMC 
group and 10.8 ± 9.8 mm Hg in the Ologen group. The reduction in IOP from baseline was 
significant in each group (p<0.001). The reduction in IOP from baseline in between the two 
groups was not statistically significant (p value=0.20). 
 
 
 
 
- 69 - 
 
10. Number of postoperative medications: 
 
4 patients in MMC group and 3 patients in the Ologen group did not achieve success 
as defined in the study. However only 1 patient had to be started on timolol drops in 
the MMC group as the IOP was not controlled. It was not statistically significant (p = 
0.338). In the rest of them, though target IOP was not achieved, there was reduction in 
the IOP following surgery. After reassessing the morphology of the optic nerve head 
it was decided to defer treatment till further follow up. These patients were planned 
for further follow up with IOP and fields after 3 months and decision of need for 
medications based on IOP and progression if any. The details of postoperative 
medications is shown in table 22. 
Table 22: Details of post operative anti-glaucoma medications at 3 months 
 Patients on no 
medication 
(%) 
Patients on 
single 
medication 
(%) 
Total (%) 
MMC 30(96.77) 1(3.23) 31(100.00) 
Ologen 28(100.00) 0(0.00) 28(100.00) 
Total 58(98.31) 1(1.69) 59(100.00) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 70 - 
 
 
 
11. Complications: 
No complications were seen in 86.44% cases. There was no statistically significant 
difference in the rate of complications in between the two groups. The details are 
described in table 23 and figure 11. 
Table 23: Distribution of various complications in the two groups 
 MMC (%) Ologen (%) P value 
Hypotony 4 (12.90) 1 (3.57) 0.199 
Hypotonic maculopathy 1(3.23) 1(3.57) 0.942 
Choroidal detachment 3(9.68) 0(0.00) 0.091 
Leak 2 (6.45) 1 (3.57) 0.615 
 
 Hypotony: 4 patients had hypotony in the MMC group as compared to only 1 patient 
in the Ologen group.Of the four patients who had hypotony in the MMC group, only 
one patient had persistent hypotony at 3 months. In the Ologen group, the one patient 
with hypotony did not recover at 3 months follow up. However, both the patients did 
not have associated hypotonic maculopathy.  
 Leak: The 2 patients in MMC group had associated transient choroidal detachment 
which resolved spontaneously. 1 of these patients required conjunctival resuturing. 1 
patient in the Ologen group had associated transient hypotonic maculopathy.   
 Hypotonic maculopathy:  In 2 patients hypotonic maculopathy was only transient 
which resolved spontaneously. 
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 Choroidal detachment: In 2 patients it was associated with wound leak, 1 patient 
required conjunctival resuturing. In 2 patients it was associated with transient 
hypotony which resolved spontaneously without any intervention. 
 
Figure 11: Graph showing distribution of complications in the two groups 
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12. Additional interventions - Needling 
 
Needling with injection 5-FU was done in 3 patients in MMC group and 1 patient in 
Ologen group. Needling resulted in achieving the desired IOP in all patients in the 
MMC group.  One of these patients developed dense exudative reaction and shallow 
anterior chamber after needling due to seepage of 5-FU into anterior chamber. He 
underwent anterior chamber reformation. In the Ologen group only one patient needed 
to undergo needling at 3 month follow up and the needling achieved success on 
subsequent follow up visit. 
 
13. Additional intervention - Resuturing: 
One patient in the MMC group required conjunctival resuturing as it was associated with 
bleb leak. 
 
14. Additional intervention – Injection 5 -FU 
During the study period, 53 patients received 5FU in the MMC and 46 patients in the 
ologen group. There was no statistically significant difference in between the MMC 
and Ologen group (p value= 0.53) and also those who achieved success and who 
failed (p value=0.47). This was calculated using the Chi Square test. It is described in 
detail in table 24. 
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Table 24: Requirement of 5-FU in the MMC and Ologen groups    
 MMC 
success (%) 
MMC failure 
(%) 
Ologen 
success (%) 
Ologen 
failure (%) 
No. of patients 
requring 5-FU 
20 4 19 2 
No. of patients 
not requring 5-
FU 
7 0 6 1 
Total no. of 5-
FU 
44 9 41 5 
Total no. of 5-
FU 
53 in MMC 46 in Ologen 
No. of 5-FU per 
patient 
1.71 1.64 
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15. Assessment of bleb morphology 
 
 
Analysis of bleb morphology was done at 3 months between the two groups - MMC and 
Ologen. Bleb morphology included bleb area score, bleb height and vascularity score as 
explained in the review of literature section. The photographs are shown in the Appendix H. 
No. of patients in each scoring level was calculated in both the Ologen and MMC group. No 
statistically significant difference was found between any of the categories. It was calculated 
usimg Chi square test and Mann Whitney test. Comparison of the bleb morphology between 
the two groups is shown in table 25-30 and figure 12-17.  
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Table 25: Bleb morphology – Scoring of the “central demarcated area-1a” in the two 
groups 
 
 MMC (%) Ologen (%) Total (%) 
1 1 (3.23) 0 (0.00) 1 (1.69) 
2 12 (38.71) 12 (42.86) 24 (40.68) 
3 16 (51.61) 16 (57.14) 32 (54.24) 
4 2 (6.45) 0 (0.00) 2 (3.39) 
5 0 (0.00) 0 (0.00) 0 (0.00) 
Total 31 (100.00) 28 (100.00) 59  (100.00) 
 
 
Figure 12: Graph showing scoring of the “central demarcated area-1a” in the two 
groups 
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Table 26: Bleb morphology– Scoring of the “maximal area-2a” in the two groups 
 MMC (%) Ologen (%) Total (%) 
1 0 (0.00) 0 (0.00) 0 (0.00) 
2 11 (35.48) 6 (21.43) 17 (28.81) 
3 17 (54.84) 22 (78.57) 39 (66.10) 
4 3 ( 9.68) 0 (0.00) 3 (5.08) 
5 0 (0.00) 0 (0.00) 0 (0.00) 
Total 31 (100.00) 28 (100.00) 59  (100.00) 
 
 
Figure 13: Graph showing scoring of the “maximal area-2a” in the two groups 
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Table 27: Bleb morphology – Scoring of the “bleb height” in the two groups 
 MMC (%) Ologen (%) Total (%) 
1 0 (0.00) 0 (0.00) 0 (0.00) 
2 18 (58.06) 10 (35.71) 28 (47.46) 
3 13 (41.94) 18 (64.29) 31 (52.54) 
4 0 (0.00) 0 (0.00) 0 (0.00) 
Total 31 (100.00) 28 (100.00) 59  (100.00) 
 
 
Figure 14: Graph showing scoring of the “bleb height” in the two groups 
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Table 28: Bleb morphology – Scoring of the “vascularity central demarcated area-3a” 
in the two groups  
 MMC (%) Ologen (%) Total (%) 
1 3 (9.68) 1 (3.57) 4 (6.78) 
2 11 (35.48) 13 (46.43) 24 (40.68) 
3 14 (45.16) 7  (25.00) 21 (35.59) 
4 3 (9.68) 7 (25.00) 10 (16.95) 
5 0 (0.00) 0 (0.00) 0 (0.00) 
Total 31 (100.00) 28 (100.00) 59  (100.00) 
 
Figure 15: Graph showing scoring of the “vascularity central demarcated area-3a” in 
the two groups 
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Table 29: Bleb Morphology – Scoring of the “vascularity maximal area-3b” in the two 
groups  
          
 MMC (%) Ologen (%) Total (%) 
1 1 (3.23) 0 (0.00) 1(1.69) 
2 14(45.16) 14(50.00) 28(47.46) 
3 13(41.94) 8(28.57) 21(35.59) 
4 3(9.68) 5(17.86) 8(13.56) 
5 0 (0.00) 1(3.57) 1(1.69) 
Total 31 (100.00) 28 (100.00) 59  (100.00) 
 
 
 
Figure 16: Graph showing scoring of the “vascularity maximal area-3b” in the two 
groups 
 
 
 
 
 
0 
2 
4 
6 
8 
10 
12 
14 
16 
1 2 3 4 5 
N
O
. O
F 
PA
TI
EN
TS
  
SCORE 
VASCULARITY MAXIMAL AREA 
MMC 
OLOGEN 
- 80 - 
 
 
Table 30: Bleb morphology – Scoring of the “vascularity non bleb conjunctiva-3c” in 
the two groups  
 MMC (%) OLOGEN (%) TOTAL (%) 
1 0 (0.00) 0 (0.00) 0 (0.00) 
2 29 (93.55) 24 (85.71) 53 (89.83) 
3 2 (6.45) 4 (14.29) 6 (10.17) 
4 0 (0.00) 0 (0.00) 0 (0.00) 
5 0 (0.00) 0 (0.00) 0 (0.00) 
TOTAL 31 (100.00) 28 (100.00) 59  (100.00) 
 
 
Figure 17: Graph showing scoring of the “vascularity non bleb conjunctiva -3c” in the 
two groups 
 
 
Subconjunctival Blood: At 3 months follow up none of the patients had subconjunctival 
hemorrhage. 
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DISCUSSION 
The primary aim of this study was to compare the safety and efficacy of MMC versus Ologen 
implant in phacotrabeculectomy surgery. 63 patients were randomized by block 
randomization, to phacotrabeculectomy with either MMC (32 patients) or Ologen implant (31 
patients). We included patients with POAG, NTG, PACG, PEX Glaucoma and OHT. Other 
similar studies
 
(6-9) have not included NTG and OHT.  
 
Different studies (6-9) have used different concentrations of MMC (0.2- 0.4 mg/ml)
 
and 
different durations of application (2-3 min)
 
. We used 0.4mg/ml MMC for 90 seconds. This is 
the concentration and duration that is routinely used in our institution with adequate success 
and less complications in our population.   
 
Ologen implant (model number-830601) with dimensions of 6mm x 2mm was used in our 
study. Marey et al., (6) and Cillino et al., (7) used the same model of Ologen implant as our 
study. Boey et al., (9) used model number – 83068 with dimensions of 7mmx4mm. 
Rosentreter et al., (8) used implant of dimensions 7mmx4mm (model number has not been 
specified) which is version 1 subtype of ologen implant. We used this model as it made up of 
atelocolagen, which is supposed to have lower immunigenecity and additional anti-
inflammatory action (173). 
 
Surgical procedure was similar in both the groups. Standard two site phacotrabeculectomy 
was performed. All patients had one releaseable and one fixed scleral flap suture and a 
conjunctival mattress suture which is the routine surgical procedure performed in our 
institution. Unlike in some other studies, the scleral flap suture in the Ologen group was not 
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made loose
 
(6-9).The use of a releasable suture ensured post-operative manipulation in the 
Ologen group where laser suturolysis is difficult to perform.  
 
Use of 5-FU in phacotrabeculectomy with Ologen in RCTs
 
(6-8) has not been described. In 
our study 5 FU was given to patients with increased vascularity of the belb as assessed by a 
glaucoma specialist irrespective of whether the patient belonged to MMC or Ologen group. 
We also looked at the difference in the requirement of post operative antifibrotics between 
the two groups. We studied bleb morphology using Moorfields bleb grading system. Marey et 
al., (6), Boey et al., (9) andCillino et al., (7) also studied bleb morphology using Moorfields 
bleb grading system. Rosentreter et al., (8) used Wurzberg bleb classification system.   
 
We defined success based on target IOP as determined for each patient individually. Success 
was defined as IOP within + 2 mm Hg of target IOP and 6 mm Hg. IOP less than 6 mm Hg 
was considered to be hypotony. Different studies have defined absolute values
 
(6-8) and 
reduction of IOPs (8-9) from baseline as success. We chose target IOP because we included 
patient with NTG in our study.  
 
We initially calculated sample size considering 5% of patients being lost to follow up as 63. 
During the course of the study, we found an increase in the dropout rate (6.35%). The 
recalculated sample size for 10% drop out was 66. However these three patients have not 
completed 3 month follow up and hence not included in the analysis.  
 
Both MMC and Ologen implant were equally effective in lowering IOP in 
phacotrabeculectomy surgery. There was no significant difference in the success rate between 
the two groups. In a similar study, Boey et al., (9) have found that MMC is more effective in 
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lowering IOP than Ologen implant after phacotrabeculectomy. However the duration of 
application of MMC in this study was longer (2 min) and a different model (83068) of 
Ologen implant was used. Rosentreter et al., (8) have also found MMC to be superior to 
Ologen in trabeculectomy. Here again the duration of MMC was 3 minutes and the size of the 
ologen implant used was larger.  Studies by Cillino et al., (7)and Marey et al., (6)which used 
the same model of Ologen implant as ours (830601) have shown no difference between the 
two groups.  
 
There was no significant difference in the additional interventions including the requirement 
of post operative 5 FU between the two groups. Other RCTs
 
(6-8) comparing Ologen and 
MMC have not used 5FU.    
 
The bleb morphology was similar in both groups in terms of bleb area, bleb height and bleb 
vascularity at 3 months. Marey et al., (6)and Rosentreter et al., (8) found  more avascular 
blebs in the MMC group as compared to the ologen group at the end 1 year. However Cillino 
et al., (7) found no significant difference between the two groups at the end of 2 years in all 
the scores. Boey et al., (9) found more vascular blebs and bleb height being lower in the 
Ologen group at 2 month follow up.  
 
Our study did not show any significant difference in the rate of complications between the 
two groups (Table 23). There were no serious complications in either group. Marey et al.,
 
(8), 
Rosentreter et al., (8) and Cillino et al., (7) similarly found no significant difference in the 
complication rates between the two groups.  
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MMC is associated with thin avascular blebs and late bleb leaks which can lead to blebitis 
and eventually sight threatening endophthalmitis
 
(3-5). The use of Ologen may overcome this 
problem. However this would require long term follow up of Ologen patients with respect to 
success and bleb morphology. The main limitation of our study is the short term follow up. 
Longer follow up will help us to compare the long term success as well as complications of 
the 2 groups. 
 
In view of the high costs of Ologen, its routine use would be justified only if we are able to 
establish, success rates similar to MMC with lesser incidence of thin walled and late leaking 
blebs on longer follow up.   The longest follow up (2 years) study by Cillino et al., (7) 
showed similar bleb morphology and success rates in both groups. There was no increased 
incidence of thin walled blebs in the MMC group (0.2 mg for 2 minutes).  
 
In conclusion, our study showed no significant difference between the two groups in terms of 
success, bleb morphology, additional interventions needed and complications. Ologen 
implant is as effective and safe as MMC in phacotrabeculectomy.  
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CONCLUSIONS  
 
 Both MMC and Ologen implant are equally efficacious in lowering IOP in 
phacotrabeculectomy surgery. There was no statistically significant difference 
between the success rates between the two groups at 6 weeks and 3 months follow 
up. 
  There was no statistically significant difference in the bleb morphology between 
the two groups.  
 The postoperative complications, need for additional interventions and 
antiglaucoma medications was similar in both the groups.  
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APPENDIX B- INFORMATION SHEET IN ENGLISH 
 
Christian Medical College, Vellore 
Department of Ophthalmology 
A randomized trial to compare the safety & efficacy of Ologen & Mitomycin in 
combined cataract & glaucoma surgery 
INFORMATION SHEET 
 
Following glaucoma surgery there is scarring at the wound site which can cause 
failure of surgery. 
 
Conventionally Mitomycin drops are used during glaucoma surgery which is known 
to reduce this scarring process and hence increase the success rate. But rarely it 
can be associated with complications like severe decrease in intraocular pressure & 
infection leading to loss of vision. It is being routinely used for all glaucoma 
surgeries.  
 
Ologen is a new implant which is placed over the wound which also decreases this 
scarring process and has been shown to be effective in a few studies. There are no 
serious complications associated with this implant over the last 10 years experience. 
Therefore we intend to compare these two methods of glaucoma surgery.  
Ologen currently costs Rs.5000 compared to Rs.50 for Mitomycin.  
 
Before surgery all patients will undergo regular investigations & examinations 
required for combined cataract and glaucoma surgery. They will be randomly divided 
into 2 groups- one receiving Mitomycin and the other receiving Ologen.  
Information for the use of the study will be obtained during the patient’s regular follow 
up visits on day 1, week 1, 6 weeks and 3 months as is usual for glaucoma surgery. 
Besides obtaining data, patients will be evaluated to determine if they require other 
additional treatments for maintaining intra-ocular pressure like sub-conjunctival  
injections, needling and laser treatment. 
 
The complications associated with combined cataract and glaucoma surgery include 
infection, irritation, repeat surgeries, inflammation, very low intra-ocular pressure, 
prolonged stay.  
 
All patient details will be kept confidential. 
In case of any problems or questions, you may contact Dr. Smita Dikshit at 
9789551261.There are totally 60 patients in the study, and findings of the study will 
be accessible to the investigator at the end of 12 months. 
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APPENDIX C - CONSENT IN ENGLISH 
 
CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title: Randomised , double blinded,  active controlled,  clinical trial to compare 
the effect of Mitomycin & Ologen implant in phacotrabeculectomy.  
Study Number:                               Subject’s Name: 
Date of Birth / Age:_______ 
 (Please tick boxes) 
I confirm that I have read and understood the information sheet dated _________ for 
the above study and have had the opportunity to ask questions. [ ] 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
trial. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. [ ] 
I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s) [ ] 
I understand that I will receive free treatment for any study related injury or adverse 
event but I will not receive and other financial compensation [ ] 
I understand that the study staff and institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I 
agree to this access [ ]  
I understand that my identity will not be revealed in any information released to third 
parties or published [ ]   
I agree to take part in the above study. [ ] 
Name:       Name of witness: 
Signature/ thumb print :     Relation to participant: 
Date:                                                                  Signature:  
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APPENDIX D- INFORMATION SHEET IN TAMIL 
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APPENDIX E- CONSENT SHEET IN TAMIL 
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APPENDIX F– DATA COLLECTION PROFORMA 
 
RCT COMPARING PHACOTRABECULECTOMY WITH MMC VS OLOGEN 
 
NAME:                                                                    HUSBAND’S/FATHER’S NAME: 
AGE/SEX:                                                               HOSPITAL NUMBER: 
ADDRESS:                                                              PHONE NUMBER:  
PATIENT SERIAL NUMBER:                                 GROUP: MMC/ OLOGEN 
DATE OF ENROLLMENT:                                     DATE OF SURGERY: 
 
PREOPERATIVE EXAMINATION:  
 
 RIGHT LEFT 
BCVA   
RAPD   
AC DEPTH    
GRADING OF CATARACT   
IOP   
CCT   
GONIOSCOPY:   
IN SITU   
OTH   
ON MANIPULATION   
HFA:   
30-2   
24-2   
10-2   
MACULAR PROGRAM   
FUNDUS:   
DISC SIZE   
NRR   
NFLD   
DISC HEMOORRHAGES   
MACULA   
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ANTIGLAUCOMA 
MEDICATIONS 
  
 
DIAGNOSIS: 
 TARGET IOP:  
INTRAOPERATIVE COMPLICATIONS: 
EYE OPERATED: 
             POSTOPERATIVE EXAMINATION: 
 DAY 1 WEEK 1 WEEK 6 3 MONTH 
DATE     
VISION/BCVA     
BLEB MORPHOLOGY     
SEILDEL’S TEST     
AC DEPTH     
CELLS/FLARE     
IOP     
HYPHEMA     
LENS     
FUNDUS:     
CHOROIDALS     
HYPOTONIC MACULOPATHY     
BLEBITIS/ENDOPHTHALMITIS     
GONIOSCOPY     
OTHERS     
ADDITIONAL INTERVENTIONS: 
BLEB MASSAGE: 
INJECTION 5 FU: 
RELEASING RELASEABLE: 
LASER SUTUROLYSIS: 
NEEDLING:                             
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 ANTIGLAUCOMA MEDICATIONS: 
MOORFIELD’S BLEB GRADING SYSTEM: 
 DAY 1 WEEK 1 WEEK 6 3 MONTH 
DATE     
BLEB AREA     
CENTRAL DEMARCATED AREA; 1a     
MAXIMAL AREA; 2a     
BLEB HEIGHT     
BLEB VASCULARITY     
CENTRAL DEMARCATED AREA; 3a     
MAXIMAL AREA; 3b     
NON BLEB CONJUNCTIVA; 3c     
SUBCONJUNCTIVAL BLOOD     
TOTAL     
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APPENDIX G  
 
Figure 14: Moorfield’s Bleb Grading System standard photographs 
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APPENDIX H – BLEB PHOTOGRAPHS WITH SCORING 
 
 
Figure 15: Area 2a with score 3 in a MMC bleb 
 
 
 
Figure 16: Area 2a with a score 2 in Ologen bleb 
 
 
 
 
 
 
 
 
- 117 - 
 
 
 
Figure 17: Area 2 a with a score 3 in Ologen bleb 
 
 
 
Figure 18: Area 2a with score 4 in MMC bleb 
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Figure 19: Height score 2 in a MMC bleb 
 
 
 
Figure 20: Height score 3 in Ologen bleb 
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Figure 21: Central demarcated area 3a with a vascularity score of 1 in a MMC bleb 
 
 
 
 
Figure 22: Central demarcated area 3a with a vascularity score of 4 in Ologen bleb 
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Figure 23: Maximal area 3b with a vascularity score of 4 in Ologen bleb 
 
 
 
Figure 24: Maximal area 3b with a vascularity score of 5 in Ologen bleb 
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Figure 25: Ologen bleb with subconjunctival haemorrhage 
 
 
 
 
Figure 26: MMC bleb with subconjunctival haemorrhage 
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Intraop Complication
Sl No Name Hosp No Age Gender Eye Group Date of InclusionDate of SurgeryBCVA RAPD IOP CCT Disc Gonioscopy Field Diagnosis Target IOP Antiglaucoma Medications
Date BCVA IOP Hyphema Siedles Uveitis Choroidals Hypotonic Maculopathy Blebitis/Endophthalmitis Bleb Height Bleb Vascularity Subconj Blood Total Score Date BCVA IOP Siedle's Hyphema Uveitis Choroidals Hypotonic Maculopathy Blebitis/Endophthalmitis Bleb Height Bleb Vascularity Subconj Blood Total Score Date BCVA IOP Hyphema Uveitis Choroidals Hypotonic Maculopathy Blebitis/Endophthalmitis Bleb Height Bleb Vascularity Subconj Blood Total Score Date BCVA IOP Hyphema Uveitis Choroidals Hypotonic Maculopathy Blebitis/Endophthalmitis Bleb Height Bleb Vascularity Subconj Blood Total Score Inj.5FU Additional procedure
Central Demarcated Area Maximal Area Central Demarcated Area Maximal Area Non Bleb Conjunctiva Central Demarcated Area Maximal Area Central Demarcated Area Maximal Area Non Bleb Conjunctiva Central Demarcated Area Maximal Area Central Demarcated Area Maximal Area Non Bleb Conjunctiva Central Demarcated Area Maximal Area Central Demarcated Area Maximal Area Non Bleb Conjunctiva
1 Sulochana 342644s 67 Female Left MMC 7.12.2011 8.12.2011 6/24J5 3 26-30 533 0.9 Open Double Arcuate POAG 14 9.12.2011 6/36J2 14 3 3 2 4 4 3 N 19 16.12.2011 6/18J2 10 3 3 3 3 3 2 N 17 19.01.2012 6/18J2 16 3 3 3 3 3 2 N 17 12.03.2012 6/9J1 14 3 3 3 3 2 2 N 16 2
2 Vasantha 342965s 55 Female Left Ologen 14.12.2011 15.12.2011 6/18J3 1 13-14 508 0.9 Open Double Arcuate NTG 10 16.12.2011 6/9J1 26 2 2 3 5 5 4 N 21 22.12.2011 6/9J1 12 2 2 3 5 5 4 N 21 27.01.2012 6/9J1 12 2 2 2 4 4 2 N 16 16.03.2012 6/6J1 8 2 2 2 4 4 2 N 16 7
3 Gunamathi 336747s 65 Female Right MMC 14.12.2011 15.12.2011 6/36J6 3 18-22 535 0.8 Closed Double Arcuate Creeping ACG 16 Misopt 3 months 16.12.2011 6/12J1 19 2 2 2 5 5 3 Y 19 22.12.2011 6/12J1 14 2 2 3 5 5 3 Y 19 27.01.2012 6/12J1 14 2 2 2 5 5 3 N 19 16.03.2012 6/12J1 13 3 3 3 2 2 2 N 15 4
4 Padmavathi 344164s 60 Female Left Ologen 20.12.2011 20.12.2011 6/36J6 2 36-38 495 TGOA Open Unreliable POAG 14 21.12.2011 6/24J4 13 2 3 3 5 5 4 Y 22 30.12.2011 6/24J4 18 2 3 2 4 4 3 Y 20 27.01.2012 6/24J2 12 2 2 2 4 4 2 N 16 23.03.2012 6/24J5 13 2 2 2 3 3 2 N 14 2
5 Baskaran 343856s 52 Male Left MMC 21.12.2011 22.12.2011 6/36J5 0 13-18 503 0.7 Open Unreliable NTG 12 23.12.2011 6/9J1 10 2 2 3 4 4 4 Y 19 28.12.2011 6/9J1 4 Positive Shallow 2 2 2 5 5 5 N 21 3.02.2012 6/6J1 10 2 2 3 4 4 3 N 18 23.03.2012 6/9J1 13 2 3 2 3 3 2 N 15 2 Conjunctival resuturing on 27.12.2011
6 Mangalam 343882s 65 Female Left MMC 21.12.2011 22.12.2011 6/60J6 1 15-20 539 Hazy viewOpen Unreliable NTG 12 23.12.2011 6/24J4 30 3 3 2 4 4 1 Y 17 30.12.2011 6/9J2 16 3 3 2 4 4 1 Y 17 3.02.2012 6/18J2 10 3 3 2 4 4 2 N 18 23.03.2012 6/36J6 14 3 3 2 2 2 2 N 14 4
7 Jaypal 344010s 65 Male Right Ologen 21.12.2011 22.12.2011 6/12J2 0 17-19 503 0.6 Open Unreliable NTG 12 23.12.2011 6/9J1 11 2 2 2 4 4 2 N 16 30.12.2011 6/9J1 13 2 2 2 4 4 3 N 17 3.02.2012 6/6J1 13 2 2 2 4 4 3 N 17 23.03.2012 6/9J2 12 2 3 2 3 3 2 N 15 1
8 Margabandhu 337137s 69 Male Right Ologen 21.12.2011 22.12.2011 6/18J2 0 25-31 589 0.8 Open Superior Arcuate POAG 16 23.12.2011 6/60J4 20 3 3 2 5 5 3 Y 21 30.12.2011 6/36J4 11 3 3 3 4 4 3 Y 17 3.02.2012 6/18J1 15 2 3 2 4 4 3 N 18 23.03.2012 6/9J1 14 2 3 2 2 2 2 N 13 2
9 Jeyaraman 395911e 63 Male Right MMC 26.12.2011 27.12.2011 6/18J3 0 23-28 534 0.7 Open Normal OHT 16 Latanoprost 1 year 28.12.2011 6/9J1 21 2 2 2 4 4 3 Y 17 6.01.2012 6/6J1 16 2 2 2 4 4 3 Y 17 10.02.2012 6/18J2 18 2 3 3 5 5 3 N 21 30.03.2012 6/6J1 16 2 2 2 4 4 2 N 16 1 Needling, AC wash& Reformation 27.01.2012; 30.01.2012
10 Elumalai 344478s 65 Male Left Ologen 26.12.2011 27.12.2011 6/12J1 0 32-33 530 0.8 Open non specific POAG 18 Diamox 1week 28.12.2011 6/18J2 35 2 2 3 5 5 4 Y 21 6.01.2012 6/9J1 26 2 2 3 5 5 4 Y 21 10.02.2012 6/6J1 19 2 2 3 3 2 2 N 14 1 LOST
11 Mir Mukhtar Hussain 204683s 63 Male Left MMC 27.12.2011 27.12.2011 6/18J3 0 36-38 591 TGOA Open Double Arcuate POAG 18 MIsopt + Latanoprost 1wk 28.12.2011 6/24J4 22 2 3 2 4 4 2 N 17 6.01.2012 6/60J7 17 2 2 3 1 2 2 N 12 10.02.2012 6/36J6 18 2 2 2 1 2 2 N 12 30.03.2012 6/36J2 14 2 2 2 1 3 2 N 12 2
12 Tamizh Selvam 341851s 58 Male Left Ologen 28.12.2011 29.12.2011 6/9J1 0 24-26 515 0.9 Open Inferior Arcuate POAG 10 30.12.2011 6/9J1 26 3 3 3 2 2 1 Y 14 6.01.2012 6/9J1 23 1 1 2 3 3 2 N 12 10.02.2012 6/9J1 11 2 2 3 3 3 2 N 15 30.08.2012 6/9J1 16 2 2 2 2 2 2 N 12 0 LOST 8 MONTH FOLLOW UP
13 Ramasamy 125922s 56 Male Right MMC 9.01.2012 18.01.2012 3/60J7 0 14-14 0.4 Open Superior Arcuate POAG 14 Lumigan 4-5years 10.01.2012 6/12J1 30 1 1 1 3 3 2 Y 11 16.01.2012 6/12J1 27 1 1 1 3 3 2 Y 11 24.02.2012 6/6J1 13 2 2 2 3 3 2 N 14 13.04.2012 6/6J1 14 2 2 2 3 3 2 N 14 1
14 Venugopal Chetty 530498e 66 Male Right Ologen 19.01.2012 20.01.2012 6/12J1 0 14-16 0.9 Open Superior Arcuate POAG 14 Pilocarpine 12 years 20.01.2012 6/12J1 12 3 3 3 4 4 4 Y 21 25.01.2012 6/6J1 14 3 3 2 4 4 3 Y 19 2.03.2012 6/6J1 12 3 3 2 4 4 3 N 19 20.02.2012 6/6J1 10 3 3 3 4 4 3 N 20 0
15 Ismail Shariff 347909s 75 Male Right MMC 30.01.2012 31.01.2012 6/36J7 0 35 562 Hazy viewOpen Not possible PEX Glaucoma 18 1.02.2012 6/12J2 23 2 2 3 4 4 3 N 18 13.02.2012 6/9J1 18 2 2 3 4 4 3 N 18 10.03.2012 6/6J1 20 3 3 3 3 3 2 N 17 27.04.2012 6/9J1 18 3 3 3 3 3 2 N 17 2 Needling 27.04.2012
16 Subramani 345828s 61 Male Left Ologen 30.01.2012 31.01.2012 HM 0 18-19 0.9 Open Not possible POAG 15 Travatan 1.02.2012 HM 18 3 3 3 3 3 3 N 18 10.02.2012 6/60J6 12 2 3 3 4 3 3 N 18 10.03.2012 6/60J7 10 3 3 2 4 3 3 N 18 0 LOST
17 Edwin 828119e 58 Male Left Ologen 30.01.2012 31.01.2012 6/6J1 3 55 520 0.9 Open Superior Arcuate POAG 18 1.02.2012 6/6J1 24 2 3 2 4 4 4 Y 19 10.02.2012 6/6J1 16 3 3 2 4 4 4 N 20 9.03.2012 6/6J1 10 3 3 2 4 4 3 N 19 27.04.2012 6/6J1 14 3 3 2 4 4 3 N 19 3
18 Mariammal 347371s 65 Female Right MMC 1.02.2012 2.02.2012 6/60J4 0 14-16 520 0.7 Open Normal NTG 10 3.02.2012 6/6J2 16 2 2 2 4 4 2 N 16 10.02.2012 6/9J1 10 2 2 2 4 4 2 N 16 16.03.2012 6/9J2 2 2 2 2 3 3 2 N 14 4.05.2012 6/12J2 10 2 2 2 3 3 2 N 14 0
19 Mari Rita 220898s 72 Female Left MMC 1.02.2012 2.02.2012 6/9J1 0 16-18 525 0.8 Open Superior Arcuate POAG 15 Travatan 1 year 3.02.2012 6/9J1 14 3 4 3 3 4 3 N 20 10.02.2012 6/6J1 23 3 3 3 3 4 3 N 19 16.03.2012 6/6J1 14 2 2 2 4 4 3 N 17 4.05.2012 6/9J1 4 1 3 2 3 3 2 N 14 2
20 Ganesan 348463s 64 Male Right Ologen 13.02.2012 14.02.2012 6/9J1 0 26,33 563 0.9 Open Superior Arcuate POAG 16 15.02.2012 6/9J1 15 2 3 3 4 5 4 Y 21 24.02.2012 6/9J1 21 2 2 3 4 4 3 Y 18 30.03.2012 6/6J1 21 2 2 3 3 3 2 N 15 18.05.2012 6/9J1 18 2 2 3 2 2 2 N 13 4
21 Bhuvaneshwari 122791s 64 Female Right Ologen 13.02.2012 15.02.2012 6/12J1 1 12,14 503 0.6 Open Superior Arcuate NTG 16 Travatan 4 months 15.02.2012 6/12J1 18 3 3 3 3 4 4 N 20 24.02.2012 6/6J1 9 3 3 3 4 3 3 N 19 30.03.2012 6/6J1 12 3 3 3 4 3 2 N 18 18.05.2012 6/9J1 12 3 3 3 2 2 2 N 15 1
22 Abdul Rahman 928163e 64 Male Left MMC 15.02.2012 16.02.2012 6/12J2 0 14,16 601 0.7 Open Unreliable POAG 15 Misopt 3 months 17.02.2012 6/9j1 16 2 2 2 4 4 3 N 17 24.02.2012 6/9J1 22 3 3 2 4 4 3 N 19 30.03.2012 6/9J1 14 3 3 2 3 3 2 N 16 18.05.2012 6/6J1 12 3 3 2 2 2 2 N 14 1
23 Mallika 349051s 49 Female Left Ologen 15.02.2012 16.02.2012 6/60J10 0 24 523 0.9 Open Tunnel vision POAG 14 Timolol 10 days 17.02.2012 6/60J7 12 3 3 3 2 2 2 N 15 24.02.2012 6/36J2 5 3 3 3 2 2 2 N 15 30.03.2012 6/9J1 5 3 3 3 1 2 2 N 14 18.05.2012 6/18J3 3 3 3 3 1 2 2 N 14 0
24 Kamsala 251155s 80 Female Left Ologen 16.02.2012 16.02.2012 6/24J4 0 19-22 510 0.6 Open Inferior Arcuate POAG 16 PC Rent, Rigid IOL 17.02.2012 6/36J5 24 2 3 3 4 4 2 Y 18 24.02.2012 6/24J5 14 2 3 3 3 3 2 N 16 30.03.2012 6/24J10 10 3 3 3 2 2 2 N 15 18.05.2012 6/60J6 14 3 3 3 2 2 2 N 15 0
25 Koush 348777s 61 Male Left MMC 20.02.2012 21.022012 6/36J6 0 24-30 550 0.9 Open Unreliable POAG 14 22.02.2012 6/9J2 20 2 2 2 4 4 3 N 17 27.02.2012 6/9J2 20 2 3 2 5 5 4 N 21 2 LOST
26 Muniammal 339488s 50 Female Left MMC 22.02.2012 23.02.2012 6/6J1 2 20,22 493 TGOA Open Double Arcuate PEX Glaucoma 12 Misopt 2 months 24.02.2012 6/9J2 6 2 3 2 4 4 3 N 18 2.03.2012 6/9J2 10 2 3 2 4 4 3 N 18 30.03.2012 6/6J1 10 3 3 3 3 3 2 N 17 25.05.2012 6/6J1 10 3 3 3 2 2 2 N 15 4
27 Lalitha 339109s 61 Female Right MMC 22.02.2012 23.02.2012 6/9J1 0 18,16 560 0.9 Open Superior Arcuate NTG 14 Timolol 6 weeks 24.02.2012 6/9J2 15 2 3 2 4 4 3 N 18 2.03.2012 6/6J1 10 3 3 2 4 4 3 N 19 30.03.2012 6/6J1 12 3 3 3 3 3 2 N 17 25.05.2012 6/6J1 10 3 3 3 3 3 2 N 17 0
28 Lakshmi Devi 350024s 56 Female Right Ologen 29.02.2012 1.03.2012 6/18J3 0 19-22 543 0.8 Open Double Arcuate NTG 12 2.03.2012 6/12J1 18 3 3 4 4 4 2 Y 20 9.03.2012 6/12J2 15 3 3 3 5 5 5 N 22 13.04.2012 6/9J1 12 3 3 3 4 4 2 N 16 1.06.2012 6/9J1 10 3 3 3 3 3 2 N 17 2
29 Mani 340946s 70 Male Left MMC 7.03.2012 8.03.2012 6/24J5 1 18,18 515 0.9 Open Double Arcuate NTG 12 9.03.2012 6/12J2 10 3 3 2 4 4 3 Y 19 16.03.2012 6/9J2 10 3 3 2 4 4 3 Y 19 20.04.2012 6/6J1 6 2 2 2 2 2 2 N 12 8.06.2012 6/6J1 10 2 2 2 2 2 2 N 12 0
30 Kasthuri 339141s 55 Female Right Ologen 7.03.2012 8.03.2012 6/60j7 0 14 519 0.3 Open Unreliable OHT 16 Timolol 2 months 9.03.2012 6/6J1 11 3 3 4 4 4 3 Y 21 16.03.2012 6/12J2 5 3 3 3 4 5 3 N 18 20.04.2012 6/9J1 10 3 3 3 4 3 3 N 16 8.06.2012 6/9J1 16 3 3 3 2 2 2 N 15 0
31 Kamala 338815s 65 Female Left Ologen 7.03.2012 29.03.2012 6/24J3 0 19-22 0.8 Open Normal PEX Glaucoma 12 30.03.2012 6/18J2 8 3 3 3 4 4 4 Y 21 7.04.2012 6/18J3 3 Positive Present 3 3 2 4 4 3 N 19 11.05.2012 6/9J1 13 3 3 2 4 4 3 N 19 29.06.2012 6/9J1 11 3 3 2 2 2 2 N 14 1
32 Mani V 864313E 67 Male Right MMC 12.03.2012 13.03.2012 6/12J4 0 18,20 538 0.7 Open Inferior Arcuate POAG 16 Misopt+Lumigan 14.03.2012 6/12J2 28 3 3 3 4 4 4 Y 21 23.03.2012 6/6J1 17 3 3 2 4 4 3 Y 19 27.04.2012 6/6J1 16 3 3 2 1 3 2 N 14 15.06.2012 6/6J1 16 4 4 3 1 2 2 N 16 2
33 Sitaraman 349295s 79 Male Left MMC 14.03.2012 15.03.2012 6/18J6 0 16,18 554 0.8 Open Superior Arcuate NTG 12 16.03.2012 6/9J1 18 3 4 3 3 3 2 Y 18 23.03.2012 6/9J1 18 3 3 2 4 4 3 Y 17 27.04.2012 6/9J1 2 Present Present 3 3 3 3 3 2 N 17 15.06.2012 6/6J1 8 4 4 3 2 2 2 N 17 3
34 Vithiya 350532s 66 Female Left Ologen 21.03.2012 22.03.2012 6/12J2 0 28,28 0.8 Open Superior Arcuate POAG 14 23.03.2012 6/60J5 7 3 3 2 3 4 3 N 19 30.03.2012 6/36J5 4 Present 3 3 2 3 4 3 N 17 4.05.2012 6//18J1 10 2 3 2 3 3 2 N 15 22.06.2012 6/12J1 12 2 2 2 2 2 2 N 12 0
35 Devamani 347948s 59 Female Right MMC 21.03.2012 22.03.2012 6/24J5 0 18,18 510 0.6 Open Unreliable NTG 14 23.03.2012 6/6J1 12 2 2 2 4 4 3 N 17 30.03.2012 6/18J5 6 2 2 2 4 4 3 N 17 4.05.2012 6/9J1 8 2 2 2 4 4 3 N 17 22.06.2012 6/6J1 10 2 2 2 4 4 3 N 17 0
36 Ramachandran 271584s 72 Male Right Ologen 28.03.2012 29.03.2012 HM 2 29 495 0.8 Closed Not possible Creeping ACG 14 30.03.2012 6/18J4 14 3 4 3 4 4 4 N 22 7.04.2012 6/18J4 8 3 4 3 4 4 3 N 21 11.05.2012 6/12J2 7 1 3 3 4 4 3 N 18 29.06.2012 6/24J4 8 3 3 3 2 2 2 N 15 1
37 Valliammal 351489s 65 Female Left MMC 11.04.2012 12.04.2012 6/12J1 0 31,30 436 0.9 Open Unreliable POAG 12 Brimonidine+Timolol 13.04.2012 6/24J4 20 3 4 3 3 3 3 N 19 20.04.2012 6/18J4 14 2 3 2 3 3 2 N 15 25.05.2012 6/12J2 15 2 2 2 3 3 2 N 15 13.07.2012 6/12J2 16 on timolo 2 2 2 2 2 2 N 12 2
38 Mercy Indra 147092s 56 Female Left Ologen 23.04.2012 24.04.2012 6/6J1 0 20,22 578 0.9 Closed Superior Arcuate Creeping ACG 18 Misopt 5 months 25.04.2012 6/6J1 14 3 3 3 4 4 3 Y 20 4.05.2012 6/9J1 10 3 3 3 5 5 3 Y 22 8.06.2012 6/6J1 14 3 3 3 4 4 3 N 20 27.07.2012 6/6J1 16 2 2 3 4 4 2 N 17 3
39 Vijaykumari 334483s 66 Female Left Ologen 23.04.2012 24.04.2012 6/9J1 0 38,38 471 0.9 Open Double Arcuate POAG 16 Dorzox T+ Alphagan 25.04.2012 6/9J1 12 3 3 3 4 4 4 Y 21 4.05.2012 6/18J3 13 3 3 3 4 4 4 N 21 8.06.2012 6/9J1 20 3 3 3 4 4 3 Y 20 27.07.2012 6/9J1 11 3 3 3 3 3 2 N 17 3
40 Ramakka 318555s 56 Female Right MMC 25.04.2012 26.04.2012 6/18J3 3 14 526 TGOA Closed Double Arcuate Chronic ACG 14 Travatan 27.04.2012 6/9J1 14 2 2 2 4 4 4 Y 18 4.05.2012 6/18J2 8 2 2 2 4 4 3 Y 17 8.06.2012 6/12J2 11 2 2 2 3 3 2 N 14 27.07.2012 6/12J1 11 2 2 2 2 2 2 N 12 3
41 Raja 331150s 65 Male Right Ologen 9.05.2012 10.05.2012 6/18J5 1 19,18 627 0.8 Open Normal NTG 16 11.05.2012 6/9j1 30 3 3 3 5 5 4 y 23 18.05.2012 6/12J2 12 3 3 3 4 4 3 Y 20 22.06.2012 6/9J1 19 2 2 2 4 4 3 Y 17 10.08.2012 6/9J1 16 2 3 3 2 2 2 N 14 3
42 Rajaram 358513s 55 Male Right MMC 30.05.2012 31.05.2012 6/18J3 3 14-18 560 0.9 Open Double Arcuate POAG 14 Timolol 1 month 1.06.2012 6/18J2 14 3 3 2 4 4 4 Y 20 8.06.2012 6/12J2 20 3 3 2 3 3 2 Y 16 6.07.2012 6/9J2 19 3 3 3 3 3 2 N 17 3.09.2012 6/12J1 15 3 3 3 3 3 2 N 17 0
43 Sridharan 297431s 43 Male Left Ologen 6.06.2012 7.06.2012 6/36J6 0 22,22 558 0.6 Open Normal OHT 18 8.06.2012 6/J1 18 3 4 3 4 4 4 Y 22 15.06.2012 6/6J1 10 3 4 3 4 4 4 Y 22 20.07.2012 6/9J1 20 3 3 3 4 4 3 N 20 7.09.2012 6/9J1 20 3 3 3 2 2 2 N 15 3
44 Athul Hasan 142332s 70 Male Right MMC 11.06.2012 12.06.2012 6/18J4 0 14-16 563 0.9 Open Superior Arcuate NTG 12 Xalatan 13.06.2012 6/18J2 23 3 3 2 4 4 3 Y 19 22.06.2012 6/18J2 13 3 3 2 4 4 3 Y 19 27.07.2012 6/9J1 14 2 2 2 4 4 3 N 17 14.09.2012 6/9J1 13 3 3 2 2 2 2 N 14 2
45 Ahmad Basha 364655s 70 Male Left MMC 18.07.2012 19.07.2012 2/60Jnil 0 18,22 503 0.8 Open Not possible POAG 15 20.07.2012 6/9J1 19 3 3 3 5 5 4 Y 20 27.07.2012 6/9J2 19 3 3 3 5 5 4 Y 20 31.08.2012 6/36J4 10 2 2 3 4 4 3 N 18 19.10.2012 6/12J3 10 3 3 3 3 3 2 N 17 1
46 Navneetham 321171s 48 Female Left Ologen 13.06.2012 14.06.2012 6/9J1 1 11,14 523 0.8 Open Superior Arcuate NTG 12 Lumigan 15.06.2012 6/9J1 8 3 4 3 5 5 4 Y 24 22.06.2012 6/6J1 2 4 4 4 4 4 4 Y 24 27.07.2012 6/6J1 11 3 3 3 4 4 3 N 20 14.09.2012 6/6J1 11 2 3 2 3 3 2 N 15 1
47 Raja Gopal 362383s 72 Male Right MMC 27.06.2012 28.06.2012 6/18J3 0 16,19 542 0.9 Open Double Arcuate NTG 11 29.06.2012 6/6J1 16 3 3 3 4 4 3 Y 20 6.07.20112 6/6J1 13 3 3 2 4 4 3 Y 19 10.08.2012 6/12J1 13 2 2 2 4 4 3 N 17 28.09.2012 6/6J1 13 2 2 2 3 3 2 N 14 2
48 Elumalai 364755s 53 Male Left MMC 4.07.2012 5.07.2012 6/18J4 0 19,20 478 0.9 Open Double Arcuate NTG 12 6.07.2012 6/6J1 19 2 3 2 5 5 4 Y 19 13.07.2012 6/12J1 19 2 2 2 5 5 3 Y 19 17.08.2012 6/9J1 13 2 3 2 3 3 2 N 15 5.10.2012 6/6J1 18 2 2 2 3 3 2 N 14 4
49 Vinayagam 364431s 54 Male Left Ologen 4.07.2012 5.07.2012 6/6J1 3 42,32 529 0.4 Open Normal PEX Glaucoma 18 6.07.2012 6/9J1 20 3 3 3 4 4 3 Y 20 13.07.2012 6/6J1 10 3 4 3 4 4 3 Y 21 17.08.2012 6/6J1 10 3 3 3 4 4 3 N 20 5.10.2012 6/6J1 12 3 3 3 2 2 2 N 15 1
50 Sankaravadivu 232078s 69 Male Right Ologen 4.07.2012 5.07.2012 6/18J3 0 14,14 516 0.8 Open Superior Arcuate POAG 10 Lumigan 6.07.2012 6/12J1 18 3 3 3 5 5 4 Y 23 13.07.2012 6/18J2 13 3 3 3 4 4 3 N 20 17.08.2012 6/12J1 20 3 3 3 4 4 3 N 20 5.10.2012 6/9J1 12 3 3 3 3 3 2 N 17 1
51 Meganathan 628604s 51 Male Left Ologen 9.07.2012 10.07.2012 6/12J1 0 17 504 0.9 Open Double Arcuate POAG 10 Latacom + Dorzox 1 week 11.07.2012 6/9J1 22 3 3 3 4 4 4 N 20 20.07.2012 6/9J1 15 3 3 3 4 4 3 N 20 24.08.2012 6/9J1 14 3 3 3 3 3 2 N 17 12.10.012 6/9J1 10 2 3 2 2 2 2 N 11 1
52 Parvathi 365845s 62 Female Right MMC 25.07.2012 2.08.2012 6/24J6 0 14-18 525 0.9 Open Superior Arcuate NTG 10 3.08.2012 6/9J1 12 2 3 2 4 4 3 Y 15 10.08.2012 6/9J1 13 2 3 2 3 3 2 N 15 14.09.2012 6/9J1 10 2 3 2 3 3 2 N 15 02.11.2012 6/9J1 16 2 2 2 3 2 2 N 13 1
53 Navneetham 367577s 75 Female Right Ologen 7.08.2012 9.08.2012 6/18J4 3 50 601 0.9 Closed Advanced Creeping ACG 18 10.08.2012 6/18J2 13 3 4 3 5 5 4 Y 24 17.08.2012 6/9J1 20 3 4 3 5 5 4 Y 24 LOST 
54 Saraswathi 369237s 72 Female Right MMC 8.08.2012 9.08.2012 6/24J4 0 18,20 538 0.8 Open Superior Arcuate NTG 14 10.08.2012 6/12J2 16 3 3 3 4 4 3 Y 20 17.08.2012 6/9J1 14 3 3 3 4 4 3 N 20 21.09.2012 6/9J1 8 3 4 3 3 3 2 N 18 09.11.2012 6/9J1 10 3 3 3 3 3 2 N 17
55 Indarani 367929s 70 Female Left Ologen 8.08.2012 16.08.2012 6/6J1 0 18,19 471 0.7 Open Double Arcuate NTG 12 17.08.2012 6/9J1 18 4 4 3 4 4 3 Y 22 24.08.2012 6/12J2 14 3 3 3 4 4 3 N 20 28.09.2012 6/9J1 16 2 3 3 3 2 2 N 15 16.11.2012 6/9J1 10 3 3 3 4 3 2 N 18 0
56 Raman 369405s 63 Male Right MMC 10.08.2012 22.08.2012 6/36J10 0 32,30 556 0.6 Open Normal POAG 18 23.08.2012 6/9J1 10 2 2 2 4 4 3 N 17 30.08.2012 6/9J1 6 2 3 2 4 4 3 N 18 4.10.2012 6/6J1 7 4 4 3 3 3 2 N 19 16.11.2012 6/9J1 8 3 3 3 2 2 2 N 15 3
57 Krishnaiah 369246s 63 Female Right MMC 14.08.2012 16.08.2012 6/24J4 2 32,30 515 0.8 Open Superior Arcuate PEX Glaucoma 13 17.08.2012 6/18J3 20 3 4 3 4 5 4 N 23 24.08.2012 6/24J3 4 3 3 3 4 4 3 N 20 28.09.2012 6/12J1 8 3 4 3 4 4 3 N 21 16.11.2012 6/18J2 10 3 3 3 3 3 2 N 17 1
58 Rajamma 364690s 69 Female Left MMC 14.08.2012 16.08.2012 2/60Jnil 0 15,18 521 0.7 Open Inferior Arcuate NTG 13 17.08.2012 6/9J1 14 2 3 2 4 4 3 N 18 24.08.2012 6/9J1 10 2 3 2 4 4 3 N 18 28.09.2012 6/6J1 10 2 4 3 2 2 2 N 15 16.11.2012 6/6J1 14 3 3 2 2 2 2 N 14 1
59 Lilly Benjamin 365904s 60 Female Right Ologen 14.08.2012 16.08.2012 6/12J2 1 20,24 514 0.9 Open Superior Arcuate POAG 12 Dorzox T 2 months 17.08.2012 6/9J1 14 2 2 2 5 5 3 Y 19 24.08.2012 6/6J1 16 2 2 2 4 4 3 Y 17 28.09.2012 6/9J1 15 2 3 3 3 3 2 N 16 16.11.2012 6/6J1 18 2 3 3 3 3 2 N 16 1
60 Subba Reddy 369328s 60 Male Right Ologen 22.08.2012 23.08.2012 6/18J3 0 24,28 511 0.5 Open Normal PEX Glaucoma 18 24.08.2012 6/6J1 9 3 3 3 4 4 3 Y 20 31.08.2012 6/6J1 10 3 3 3 4 4 3 N 20 5.10.2012 6/6J1 8 3 3 3 4 4 3 N 20 20.11.2012 6/6J1 14 3 3 3 4 4 3 N 20 0
61 Thulasi Raman 336829s 69 Male Right Ologen 22.08.2012 23.08.2012 6/12J2 2 30,34 575 0.8 Open Double Arcuate POAG 15 24.08.2012 6/60Jnil 50 3 3 3 4 5 4 y 22 31.08.2012 6/9J3 20 3 3 3 4 4 3 N 20 5.10.2012 6/9J3 24 3 3 3 4 4 3 Y 20 16.11.2012 6/12J1 26 3 3 3 4 5 3 N 21 4 Needling 16.11.2012
62 Munisamy 371461s 66 Male Right MMC 29.08.2012 30.08.2012 3/60Jnil 0 14,18 496 0.9 Open Superior Arcuate NTG 12 31.08.2012 6/18J2 0 Positive 3 3 2 4 4 3 N 19 7.09.2012 3/60Jnil 4 Shallow 3 3 2 4 4 3 N 19 12.10.2012 6/9J2 4 3 3 2 1 1 2 N 12 20.11.2012 6/9J2 8 3 3 2 1 1 2 N 12 0
63 Dilshad 330692s 48 Female Left MMC 29.08.2012 30.08.2012 6/12J2 3 18,24 469 TGOA Closed Double Arcuate ACG 15 Misopt 31.08.2012 6/18J2 30 3 3 3 4 4 3 Y 20 7.09.2012 6/36J6 16 3 4 3 5 5 4 N 24 12.10.2012 6/36J8 25 3 4 3 4 4 3 Y 23 20.11.20126/12J1 16 3 4 3 4 4 3 N 21 4 Needling 12.10.2012
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